

# ADVANCED PHARMACEUTICAL AND HERBAL NANOSCIENCE FOR TARGETED DRUG DELIVERY SYSTEMS PART II

**Editors:**  
**Swarnlata Saraf**  
**Ram Kumar Sahu**  
**Vivek Dave**

**Bentham Books**



# **Advanced Pharmaceutical Herbal Nanoscience: Targeted Drug Delivery System**

## ***Part II***

Edited by

*Chief Editor:*

**Prof. (Dr.) Swarnlata Saraf**

*Professor & Director, University Institute of Pharmacy,  
Pt Ravishankar Shukla University,  
Raipur-492010, Chhattisgarh, India*

*Editor:*

**Dr. Ram Kumar Sahu**

*Assistant Professor, Department of Pharmaceutical Science,  
Sushruta School of Medical  
and Paramedical Sciences,  
Assam University (A Central University),  
Silchar-788011, Assam, India*

&

**Dr. Vivek Dave**

*Associate Professor & Head, Department of  
Pharmacy, School of Health Science,  
Central University of South Bihar,  
Bihar-824236, India*

**Advanced Pharmaceutical Herbal Nanoscience:  
Targeted Drug Delivery System (Part II)**

Editors: Swarnlata Saraf, Ram Kumar Sahu and Vivek Dave

ISBN (Online): 978-981-5036-54-1

ISBN (Print): 978-981-5036-55-8

ISBN (Paperback): 978-981-5036-56-5

© 2022, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

## **BENTHAM SCIENCE PUBLISHERS LTD.**

### **End User License Agreement (for non-institutional, personal use)**

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [permission@benthamscience.net](mailto:permission@benthamscience.net).

### **Usage Rules:**

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

### ***Disclaimer:***

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

### ***Limitation of Liability:***

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

### **General:**

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

**Bentham Science Publishers Pte. Ltd.**

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: [subscriptions@benthamscience.net](mailto:subscriptions@benthamscience.net)



## CONTENTS

<b>FOREWORD</b> .....	i
<b>PREFACE</b> .....	ii
<b>LIST OF CONTRIBUTORS</b> .....	iv
<b>CHAPTER 1 PHARMACEUTICAL NANOSCIENCES AND THEIR APPLICATION IN THE DELIVERY OF VARIOUS PHYTOCONSTITUENTS</b> .....	1
<i>Retno Widyowati and Andang Miatmoko</i>	
<b>INTRODUCTION</b> .....	2
<b>PHYTOCONSTITUENTS IN HERBAL MEDICINE</b> .....	3
Phenolic .....	3
Terpenoid .....	5
Alkaloid .....	6
Anthraquinone .....	7
<b>NANOTECH FOR THE DELIVERY OF DIFFERENT PHYTOCONSTITUENTS</b> .....	8
Liposome .....	9
Microemulsion .....	10
Solid Lipid Nanoparticles and Nanostructured Lipid Carriers .....	11
Inorganic Nanoparticles .....	13
Liquid Crystalline Systems .....	13
<b>POLYMER NANOPARTICLES</b> .....	14
Dendrimers .....	16
<b>THERAPEUTICAL APPLICATION</b> .....	17
Cancer .....	18
Rheumatoid .....	18
Nutraceutical Delivery .....	21
<b>CONCLUSION</b> .....	24
<b>CONSENT FOR PUBLICATION</b> .....	24
<b>CONFLICT OF INTEREST</b> .....	24
<b>ACKNOWLEDGEMENTS</b> .....	24
<b>REFERENCES</b> .....	24
<b>CHAPTER 2 DESIGN OF COSMECEUTICAL DRUG DELIVERY SYSTEM: ROLE OF NANOTECHNOLOGY IN COSMECEUTICALS</b> .....	33
<i>Vipin Kumar, Pankaj Bhatt, Mayank Kumar Malik and Arun Kumar</i>	33
<b>INTRODUCTION</b> .....	34
Merits of Nanocosmeceuticals .....	35
Demerits Of Nano Cosmeceuticals .....	35
<b>NOVEL NANOCARRIERS IN COSMECEUTICALS</b> .....	36
Niosomes .....	36
Liposomes .....	37
Nanocapsule .....	38
Lipid Nanoparticles And Lipid Nano-Carriers (SLN And NLC) .....	39
Nanogold and Nanosilver .....	40
Nanoemulsions .....	41
Nano Sphere .....	41
Cubosomes .....	43
<b>MAJOR NANOCOSMECEUTICAL CLASS</b> .....	44
Skincare .....	44
Haircare .....	44

Lip Care .....	45
Nail Care.....	45
<b>NANOTECHNOLOGY IN HERBAL DRUGS- NANOPHYTOMEDICINE .....</b>	<b>45</b>
Nanocurcumin.....	45
Green Nanotechnology (Cumin- Mediated Gold Nanoparticle).....	46
Ayurvedic Bhasma.....	46
Aloe Vera Extract In Nanoparticles .....	46
<b>EMERGING CHALLENGES AND POTENTIAL SOLUTIONS .....</b>	<b>47</b>
Cellular Toxicity Of Zinc Oxide And Titanium Dioxide Nanoparticles.....	47
Occupational Risks Of Nanoparticles .....	48
Potential Solutions .....	48
<i>Physical-Chemical Properties.....</i>	<i>49</i>
<i>Mathematical Modelling.....</i>	<i>49</i>
<i>Microscopic Techniques.....</i>	<i>49</i>
<i>In vitro methods.....</i>	<i>49</i>
<b>FUTURE PROSPECT OF NANOTECHNOLOGY IN NANO COSMECEUTICALS.....</b>	<b>49</b>
<b>CONCLUSION.....</b>	<b>50</b>
<b>CONSENT FOR PUBLICATION.....</b>	<b>51</b>
<b>CONFLICT OF INTEREST.....</b>	<b>51</b>
<b>ACKNOWLEDGEMENTS .....</b>	<b>51</b>
<b>REFERENCES .....</b>	<b>51</b>
<b>CHAPTER 3 TRANSFERSOME: A NOVEL VESICULAR TRANSDERMAL DELIVERY SYSTEM .....</b>	<b>59</b>
<i>Nagaraja Sreeharsha and Santosh Fattepur</i>	
<b>INTRODUCTION .....</b>	<b>60</b>
<b>ADVANTAGES AND DISADVANTAGES.....</b>	<b>60</b>
<b>COMPOSITION AND ITS MECHANISM.....</b>	<b>62</b>
<b>TRANSFERSOMES PENETRATION MECHANISM .....</b>	<b>63</b>
<b>APPLICATION OF TRANSFERSOMES AS THE TRANSDERMAL DELIVERY SYSTEM .....</b>	<b>64</b>
Delivery of Antioxidant .....	64
Delivery of Anticancer Drug.....	65
Delivery of Corticosteroids.....	65
Delivery of Anti-inflammatory Drugs.....	65
Delivery of Insulin .....	65
Delivery of Protein and Peptide .....	66
Delivery of Interferon .....	66
Delivery of Anesthetics.....	66
Delivery of NSAIDs .....	67
<b>DELIVERY OF HERBAL DRUG .....</b>	<b>67</b>
<b>REGULATORY ASPECTS.....</b>	<b>67</b>
<b>LIMITATION OF TRANSFERSOMES .....</b>	<b>69</b>
<b>FUTURE PERSPECTIVE.....</b>	<b>69</b>
<b>CONCLUSION.....</b>	<b>69</b>
<b>CONSENT FOR PUBLICATION.....</b>	<b>70</b>
<b>CONFLICT OF INTEREST.....</b>	<b>70</b>
<b>ACKNOWLEDGEMENTS .....</b>	<b>70</b>
<b>REFERENCES .....</b>	<b>70</b>
<b>CHAPTER 4 SELF-NANO/MICRO EMULSIFIED DRUG DELIVERY SYSTEM .....</b>	<b>73</b>
<i>Vishal Trivedi and Jiyauddin Khan</i>	

<b>INTRODUCTION</b> .....	73
<b>HERBAL MEDICINE IS A NOVEL DRUG DELIVERY SYSTEM</b> .....	74
<b>HERBAL NANOMEDICINES OF SNEDDS AND SMEDDS</b> .....	74
<b>SELF EMULSIFICATION PROCESS</b> .....	77
Self-Nano Emulsifying Drug Delivery System (SNEDDS) .....	77
Self-Micro Emulsifying Drug Delivery System (SMEDDS) .....	77
<b>INGREDIENTS REQUIRED FOR THE FORMATION OF SELF-EMULSIFICATION</b>	
<b>DRUG DELIVERY SYSTEM</b> .....	77
Excipients .....	77
Surfactants .....	78
Co-Surfactant .....	78
<b>IMPORTANT OF SEDDS</b> .....	79
<b>MECHANISM OF SEDDS</b> .....	79
<b>DOSAGE FORMS FROM SEDDS</b> .....	80
Dry Emulsions .....	80
Sustained and Controlled-release Tablets .....	80
Self-emulsifying Suppositories .....	80
Implants of Self-emulsifying.....	80
<b>DRUG PROPERTIES AND CHARACTERIZATION OF SEDDS</b> .....	81
For the Characterisation of SEDDS .....	81
<b>BIOAVAILABILITY ENHANCEMENT OF DRUGS BY SEDDS</b> .....	81
<b>SNEDDS AND SMEDDS IMPROVED DISSOLUTION RATE AND BIOAVAILABILITY</b>	
<b>OF POORLY SOLUBLE DRUG</b> .....	82
Surfactants' Effect .....	82
Lipids' Effect .....	82
P-glycoprotein Inhibition .....	83
<b>SNEDDS AND SMEDDS DRUG DELIVERY SYSTEM FOR IMPROVING THE</b>	
<b>BIOAVAILABILITY/LYMPHATIC UPTAKE/LIVER UPTAKE/ PEPTIDE</b> .....	83
<b>ADVANTAGES OF SELF-EMULSIFYING DRUG DELIVERY</b> .....	84
<b>DISADVANTAGES OF SELF-EMULSIFYING DRUG DELIVERY SYSTEMS</b> .....	84
<b>EMERGING CHALLENGES AND POTENTIAL SOLUTIONS OF SNEDDS AND</b>	
<b>SMEDDS</b> .....	84
<b>MARKETED PRODUCTS OF SEDDS</b> .....	85
<b>FUTURE PROSPECTS</b> .....	86
<b>CONCLUSION</b> .....	86
<b>CONSENT FOR PUBLICATION</b> .....	86
<b>CONFLICT OF INTEREST</b> .....	87
<b>ACKNOWLEDGEMENTS</b> .....	87
<b>REFERENCES</b> .....	87

**CHAPTER 5 PHYTOSOMES** ..... 94

*Ram Kumar Sahu and Vinod Nautiyal*

<b>INTRODUCTION</b> .....	94
Phytosome/Herbosome/Pharmacosome/Liposome .....	95
Phytosome or Herbosome .....	95
Pharmacosomes .....	95
Liposomes.....	95
<b>PHYTOSOME VS. LIPOSOME</b> .....	95
<b>PREREQUISITES FOR PHYTOSOME/HERBOSOME/LIPOSOME FORMATION</b> .....	96
Selection of Active Phytoconstituents or Standardized Extract .....	96
Phospholipids.....	96



Structure of Phospholipids .....	96
Glycerophospholipids .....	96
Sphingomyelins .....	97
<b>PHYTO-PHOSPHOLIPID COMPLEX: PHYTOSOME TECHNOLOGY .....</b>	<b>97</b>
<b>PROPERTIES OF HERBOSOMES (PHYTOPHOSPHOLIPID COMPLEX).....</b>	<b>98</b>
Physical Properties.....	98
Chemical Properties.....	98
Biological Properties.....	99
<b>MERITS OF PHYTOPHOSPHOLIPID COMPLEXES (HERBOSOMES).....</b>	<b>99</b>
<b>PREPARATION OF HERBOSOMES .....</b>	<b>100</b>
Phospholipids.....	100
Solvents .....	100
Phytoconstituents .....	101
<b>METHODS OF PREPARATION OF HERBOSOMES.....</b>	<b>101</b>
Anti-solvent Precipitation .....	102
Solvent Evaporation Method .....	102
Ether Injection Method .....	102
Rotary Evaporation Method.....	103
<b>NOVEL METHODS FOR HERBOSOMES PREPARATION .....</b>	<b>103</b>
<b>DOSAGE FORMS OF HERBOSOMES .....</b>	<b>103</b>
Capsules.....	103
Hard Gelatin Capsule .....	103
Soft Gelatin Capsule .....	104
Tablets .....	104
Topical Preparations .....	104
<b>OPTIMIZATION OF HERBOSOMES.....</b>	<b>104</b>
<b>CHARACTERIZATION OF HERBOSOMES.....</b>	<b>105</b>
Partition Coefficient and Solubility .....	105
Particle Size and Zeta Potential.....	105
Yield .....	105
Entrapment Efficiency .....	106
Crystallinity and Polymorphism .....	106
Stability of Vesicles .....	106
Transition Temperature.....	106
Measurement of Surface Tension Activity.....	106
Drug Release.....	107
Spectroscopic Confirmation of Herbosomes.....	107
Fourier Transform IR Spectroscopy.....	107
Proton NMR (1H NMR) .....	107
13C NMR .....	107
SEM/TEM .....	108
X-Ray Diffraction .....	108
<b>MARKETED HERBOSOMES .....</b>	<b>108</b>
<b>LIMITATIONS OF HERBOSOMES.....</b>	<b>112</b>
<b>FUTURE PERSPECTIVES OF HERBOSOMES .....</b>	<b>112</b>
<b>CONCLUSION.....</b>	<b>113</b>
<b>CONSENT OF PUBLICATION .....</b>	<b>113</b>
<b>CONFLICT OF INTEREST .....</b>	<b>113</b>
<b>ACKNOWLEDGEMENTS .....</b>	<b>114</b>
<b>REFERENCES .....</b>	<b>114</b>

<b>CHAPTER 6 ROLE OF NANOMEDICINES IN OCULAR TARGETING DRUG DELIVERY SYSTEMS</b> .....	116
<i>Claire Faye C. Zipagan and Erwin Martinez Faller</i>	
<b>INTRODUCTION</b> .....	116
<b>THE HUMAN EYE</b> .....	117
<b>DISEASES OF THE HUMAN EYE</b> .....	120
<b>OCULAR DRUG ADMINISTRATIONS</b> .....	121
<b>BARRIERS OF THE EYES</b> .....	123
Barriers in Intravitreal Injections .....	123
Barriers in Subretinal Injections.....	124
Barriers in Intravenous Administration.....	125
Barriers in Suprachoroidal Administration.....	125
Barriers Encountered After Transscleral Administration .....	125
<b>NANOTECHNOLOGY</b> .....	126
<b>NANOTECHNOLOGY IN OCULAR DISEASES</b> .....	127
<b>NANOTECHNOLOGY IN THE DIAGNOSIS OF OCULAR DISEASE</b> .....	128
<b>NANOSYSTEMS FOR THE TREATMENT OF ANTERIOR OCULAR DISEASE</b> .....	129
<b>NANOSYSTEMS FOR THE TREATMENT OF POSTERIOR OCULAR DISEASE</b> .....	130
<b>NANOSYSTEMS FOR THE TREATMENT OF GLAUCOMA</b> .....	131
<b>EXOSOMES IN THE TREATMENT OF OCULAR DISEASES</b> .....	132
<b>EMERGING STRATEGIES IN OCULAR DRUG DELIVERY BASED ON NANOMEDICINE</b> .....	133
Contact Lens .....	133
Hydrogels.....	134
Liposomes.....	135
Niosomes .....	135
Solid Lipid Nanoparticle (SLN).....	136
Nanostructured Lipid Carrier (NLC).....	136
Inorganic Nanoparticles .....	136
Polymeric Micelles .....	136
Nanosuspension .....	136
Nanoemulsions .....	136
Light-Responsive Nanoparticles .....	137
Mesoporous Silica Nanoparticles.....	137
<b>FUTURE DIRECTIONS</b> .....	137
<b>CONCLUSION</b> .....	138
<b>CONSENT OF PUBLICATION</b> .....	138
<b>CONFLICT OF INTEREST</b> .....	138
<b>ACKNOWLEDGEMENTS</b> .....	138
<b>REFERENCES</b> .....	138
<b>CHAPTER 7 COLLOIDOSOME AS AN EFFICIENT NOVEL DRUG DELIVERY SYSTEM: AN UPDATE</b> .....	141
<i>Payal Kesharwani, Ankit Jain, Smita Jain, Vivek Dave and Swapnil Sharma</i>	
<b>INTRODUCTION</b> .....	141
<b>NATURAL POLYMERS FOR THE MANUFACTURING OF COLLOIDOSOMES</b> .....	143
Chitosan.....	143
Alginate .....	144
Cellulose.....	144
Dextran .....	144
Gelatin .....	145

<b>SYNTHESIS OF COLLOIDOSOMES.....</b>	<b>145</b>
Emulsion Based Approach.....	145
Solvent Evaporation Method .....	147
Cross-linked Colloidosomes .....	148
Layer-by Layer .....	148
Thermal Annealing .....	149
Gel Trapping Technique .....	150
<b>TYPES OF COLLOIDOSOMES.....</b>	<b>150</b>
Patchy Colloidosomes.....	150
Aqueous Core Colloidosomes.....	151
Responsive Colloidosomes .....	152
Coated Colloidosomes .....	153
Hybrid Colloidosomes .....	153
<b>STABILITY OF COLLOIDOSOMES .....</b>	<b>153</b>
<b>APPLICATION .....</b>	<b>155</b>
Colloidosomes for Target Drug Delivery.....	155
Tumour Targeting .....	156
Brain Targeting.....	156
Colloidosomes as a Carrier of a Drug .....	157
<i>Delivery of Small Molecules.....</i>	<i>157</i>
<i>Biological Molecules.....</i>	<i>157</i>
Colloidosomes for Controlled and Sustained Release.....	157
Colloidosomes for Cosmetic and Dermatology .....	158
<b>CONCLUSION AND FUTURE PROSPECTIVE .....</b>	<b>159</b>
<b>CONSENT FOR PUBLICATION .....</b>	<b>159</b>
<b>CONFLICT OF INTEREST .....</b>	<b>159</b>
<b>ACKNOWLEDGEMENTS .....</b>	<b>159</b>
<b>REFERENCES .....</b>	<b>160</b>

## **CHAPTER 8 HERBAL NANOSCIENCE: CHALLENGES AND REGULATORY**

<b>PERSPECTIVE.....</b>	<b>166</b>
<i>Vishal Soni, Priyanka Soni, Ritika Gururani and Jaya Dwivedi</i>	
<b>INTRODUCTION .....</b>	<b>167</b>
Advantages of Herbal Drugs.....	168
Drug Delivery Systems Based On Nanomedicines .....	168
Requirement For Nano based Delivery System for Herbal Remedies.....	168
Advantages of Novel Drug Delivery System .....	169
Regulatory Guidelines For Herbal Nanomedicines.....	170
Indian Regulations and Strategy .....	170
Quality Control Associated With Herbal Medicinal Products.....	171
European Regulations And Guidelines .....	172
Regulatory Challenges For Herbal Nanomedicines .....	174
Challenges Associated With The Regulatory Status Of Herbal-based Medicines.....	174
Challenges Associated With The Evaluation Of Safety And Efficacy .....	174
Challenges Associated With Quality Control Of Herbal-based Medicines .....	174
Challenges Associated With The Safety Evaluation Of Herbal Medicines .....	175
Regulations .....	175
Changes in Regulations Of Herbal Medicines Worldwide.....	175
Herbal Nanomedicines Already Approved For Clinical Use .....	177
Category 1: Indigenous Herbal Medicines.....	177
Category 2: Herbal Medicines In Medicine systems.....	177

Category 3: Modified Herbal Medicines .....	177
Category 4: Imported Products With Herbal Medicine Base .....	177
Emerging Challenges and Potential Solutions.....	178
Future Prospects.....	178
<b>CONCLUSION.....</b>	<b>180</b>
<b>CONSENT FOR PUBLICATION.....</b>	<b>180</b>
<b>CONFLICT OF INTEREST.....</b>	<b>180</b>
<b>ACKNOWLEDGEMENTS .....</b>	<b>180</b>
<b>REFERENCES .....</b>	<b>180</b>
<b>CHAPTER 9 DENDRIMERS: A VERSATILE NANOPLATFORM FOR ADVANCED TARGETING AND BIOACTIVE(S) DELIVERY.....</b>	<b>185</b>
<i>Priya Shrivastava1, Udit Agrawal, Rajeev Sharma and S.P. Vyas</i>	
<b>INTRODUCTION .....</b>	<b>185</b>
<b>POTENTIAL APPLICATIONS OF DENDRIMERS .....</b>	<b>188</b>
Dendrimers in Targeted Delivery of Bioactive(s) .....	188
Dendrimers in Oral Delivery of Bioactive(s) .....	189
Dendrimers in Ocular Delivery of Bioactive(s).....	190
Dendrimers in Microvascular Extravasation .....	191
Dendrimers in Intracellular Delivery of Bioactive(s) .....	191
Dendrimers in Tuberculosis Therapy .....	192
Dendrimers in CNS Delivery of Bioactive(s).....	193
Dendrimers in Transdermal/topical Delivery of Bioactive(s).....	196
<b>CONCLUSION.....</b>	<b>196</b>
<b>CONSENT FOR PUBLICATION.....</b>	<b>196</b>
<b>CONFLICT OF INTEREST.....</b>	<b>196</b>
<b>ACKNOWLEDGEMENTS .....</b>	<b>196</b>
<b>REFERENCES .....</b>	<b>197</b>
<b>CHAPTER 10 TARGETED DRUG DELIVERY SYSTEM TO CELL AND CELL ORGANELLES.....</b>	<b>202</b>
<i>Kenny Shane P. Alojado and Erwin Martinez Faller</i>	
<b>INTRODUCTION .....</b>	<b>202</b>
<b>CROSSING CELLULAR BARRIERS .....</b>	<b>203</b>
Lipid-Based Drug Delivery System .....	204
<b>CANCER RESEARCH AND CELLULAR DRUG DELIVERY SYSTEM .....</b>	<b>205</b>
<b>GOAL OF THE DRUG DELIVERY SYSTEM.....</b>	<b>208</b>
<b>EXTRACELLULAR VESICLE-BASED DRUG DELIVERY SYSTEM.....</b>	<b>208</b>
<b>IMPORTANCE OF EV-BASED DRUG DELIVERY SYSTEM.....</b>	<b>209</b>
<b>EXOSOMES AS NOVEL SHUTTLE DELIVERY .....</b>	<b>210</b>
<b>MITOCHONDRIA-TARGETED DRUG DELIVERY .....</b>	<b>212</b>
<b>MACROPHAGE DRUG DELIVERY .....</b>	<b>213</b>
<b>CARRIER-BASED DRUG DELIVERY SYSTEM.....</b>	<b>215</b>
<b>CONCLUSION.....</b>	<b>217</b>
<b>FUTURE DIRECTIONS.....</b>	<b>218</b>
<b>CONSENT OF PUBLICATION .....</b>	<b>218</b>
<b>CONFLICT OF INTEREST.....</b>	<b>218</b>
<b>ACKNOWLEDGEMENT .....</b>	<b>218</b>
<b>REFERENCES .....</b>	<b>218</b>
<b>CHAPTER 11 NANOTOXICOLOGY: CURRENT ISSUES AND FUTURE DIRECTIONS.....</b>	<b>220</b>
<i>Maria Maichol P. Ababan and Erwin Martinez Faller</i>	

<b>INTRODUCTION</b> .....	220
Immune System .....	221
<b>PHYSICOCHEMICAL IDENTIFICATION OF NANOMATERIALS</b> .....	221
<b>ROLE OF NANOPARTICLES IN CANCER DIAGNOSIS AND TREATMENT</b> .....	221
<b>KNOWING THE IMMUNE SYSTEM'S PART IN NANOPARTICLE DECOMPOSITION</b> .....	222
<b>UTILIZING NANOPARTICLES IN DIMINISHING TOXICITIES OF CONVENTIONAL</b>	
<b>MEDICINES</b> .....	222
<b>TOXICITY TESTING</b> .....	223
<b>CONCLUSION</b> .....	223
<b>FUTURE DIRECTIONS OF NANOTOXICOLOGY</b> .....	224
<b>CONSENT FOR PUBLICATION</b> .....	224
<b>CONFLICT OF INTEREST</b> .....	224
<b>ACKNOWLEDGEMENTS</b> .....	224
<b>REFERENCES</b> .....	225
<b>CHAPTER 12 LIPOSOMES FOR HERBAL DRUG DELIVERY</b> .....	227
<i>Andang Miatmoko, Devy Maulidya Cahyani and Retno Widyowati</i>	
<b>INTRODUCTION</b> .....	227
Liposomes as Drug Carriers .....	232
Preparation of Liposomes .....	232
Manufacturing of Liposomes .....	237
1. Thin Film Hydration .....	238
2. Reverse Phase Evaporation .....	239
3. Ethanol Injection .....	240
The use of liposomes for herbal product delivery .....	240
1. Liposomes increase herbal drugs solubility .....	240
2. Liposomes improve the bioavailability and pharmacological effects of herbal drugs .....	244
The use of nanoliposomes for enhanced drug delivery .....	247
Long Circulating Liposomes .....	248
Ligand Targeting Liposomes .....	248
Factors Affecting the Encapsulation of Herbal Extract in Liposomes .....	250
<b>CONCLUSION</b> .....	251
Future Prospective .....	252
<b>CONSENT FOR PUBLICATION</b> .....	252
<b>CONFLICT OF INTEREST</b> .....	252
<b>ACKNOWLEDGEMENTS</b> .....	252
<b>REFERENCES</b> .....	252
<b>CHAPTER 13 AI IN PHARMACY, HERBAL MEDICINE AND DRUG DELIVERY: A SCI-FI</b>	
<b>OR A REALITY</b> .....	259
<i>Srija Sur, Prashansa Sharma and Vivek Dave</i>	
<b>INTRODUCTION</b> .....	259
<b>HISTORY OF AI</b> .....	261
<b>IMPORTANCE OF ARTIFICIAL INTELLIGENCE</b> .....	264
Advantages .....	265
<b>RISK AND DISADVANTAGE OF AI</b> .....	267
<b>ROBOTS AND ARTIFICIAL INTELLIGENCE</b> .....	270
<b>POLICY OF AI</b> .....	273
AI Policy of India .....	275
<i>Fairness, Ethics, and Human Rights</i> .....	276
<i>Encouraging AI Research</i> .....	277
<i>Other Laws which Directly or Indirectly Influence AI</i> .....	277

<i>Consumer Protection Law</i> .....	278
<b>TOOLS OF ARTIFICIAL INTELLIGENCE</b> .....	278
IBM Watson for Oncology .....	278
Erica Robot.....	279
TUG Robots.....	279
Robot Pharmacy.....	279
MEDi Robot.....	280
Magnetolectric Nanorobots .....	280
DNA Nanorobots .....	280
<b>DRUG DISCOVERY AND DRUG DESIGN</b> .....	281
QSAR Studies .....	281
Eve- the Scientist Robot.....	282
Insilico Medicines.....	282
Artificial Intelligence Related Start-ups.....	283
<b>APPLICATION OF AI IN HEALTHCARE AND PHARMACY</b> .....	283
Customised Treatment .....	283
<b>CLINICAL TRIAL RESEARCH</b> .....	283
<b>DATA MANAGEMENT</b> .....	284
Cancer Diagnosis .....	285
Epidemic Outbreak Prediction .....	285
Accessible Healthcare .....	285
The Future Aspect of AI .....	286
<i>Robotic Scientists</i> .....	286
<i>Automated Transport</i> .....	286
<i>Taking over Dangerous Jobs</i> .....	286
<i>Robotic Friend</i> .....	286
<i>Robots as Caretakers</i> .....	286
<i>Robots as a Pet</i> .....	287
<i>Robot-assisted Surgery</i> .....	287
<i>Artificial Intelligence on Herbal Medicine</i> .....	287
<b>CONCLUSION</b> .....	290
<b>CONSENT OF PUBLICATION</b> .....	290
<b>CONFLICT OF INTEREST</b> .....	290
<b>ACKNOWLEDGEMENTS</b> .....	290
<b>REFERENCES</b> .....	290

<b>SUBJECT INDEX</b> .....	294
----------------------------	-----

## FOREWORD



**Prof. Sanjay Singh,**  
Vice Chancellor,  
Babasaheb Bhimrao Ambedkar University  
(A Central University),  
Lucknow, Uttar Pradesh  
India

Currently, various drug delivery systems are being developed to minimize drug degradation, prevent toxic effects, improve drug bioavailability, and increase drug accumulation at the disease target site. Nano based drug delivery offers significant advantages in terms of targeted drug delivery, transport, and release to achieve better therapeutic efficacy. This system is rapidly becoming one of the most important tools in the field of nanomedicine.

In the book titled "**Advance Pharmaceutical Herbal Nanoscience: Targeted Drug Delivery System Part II**," the author aims to provide a comprehensive overview of herbal nanoscience, including its production, evaluation, regulatory perspective and application. Herbal drugs are widely used worldwide, and their therapeutic efficacy depends on the nature of active constituents. The higher molecular weight and aqueous solubility of active ingredients, which cannot penetrate the lipid membranes of cells, lead to a decrease in bioavailability and efficacy. The combination of herbal medicine and nanotechnology has been widely recommended as nanostructured systems have the potential to overcome the above limitations. The nano-based delivery system improves the bioavailability of herbal medicines by delivering a sufficient amount of the drug to the target site of the disease.

In this book, an overview of recent advances in plant-based nanomedicine is presented. Each chapter attempts to describe the introduction, concept, progress, current status, and future prospects of plant-based nanomedicine. In addition, the book includes an overview of research in the field of plant-based nanoscience and some of the most fascinating findings from this study. The book also examined the difficulties and regulatory implications of plant-based nanoscience.

The authors of this book have succeeded in addressing the development that has been attempted in the area of novel plant-based drug delivery. This is a useful book and resource for undergraduate students, graduate students, researchers, and academicians who are exploring concepts for a nano-based drug delivery system and its performance.

## PREFACE

The objective of the book entitled “**Advanced Pharmaceutical Herbal Nanoscience: Targeted Drug Delivery System**” is to offer an understanding of various herbal novel drug delivery systems, their preparations, characterization and exciting range of applications. Herbal nanoscience targeted drug delivery system demands a broad range of awareness in novel drug delivery systems. It is very important to have detailed knowledge and awareness of new technology or new process about the various herbal nanoscience products and their composition. The awareness of knowledge about the properties of various herbal constituents of a nanoformulation is also very important because it decides the determination of the formulation of the delivery systems and broadly ensures its properties. This book covers a broad spectrum of herbal nanoscience topics required to appropriately give formulation procedure, evaluation and applications of herbal drug delivery systems and correlate it with treating many diseases.

It expresses huge awareness and knowledge regarding advanced pharmaceutical, herbal nanoscience targeted drug delivery systems in the aspect of the application in drug delivery and herbal nanomedicine. In addition to this, the book covers all major topics like drug development issues, adaptation to clinical use, market prospects and industrial commercialization too, which come under advanced pharmaceutical nanoscience and nanotechnology application. Apart from the application section, it discusses in detail the safety, herbal nanotechnology, regulatory, targeting aspects and social scenario of pharmaceutical nanoscience. The book not only focuses on theoretical knowledge but also considers practical aspects. The book is quite beneficial for students and researchers across the globe who are indulged in the reading and investigation of advanced pharmaceutical, herbal nanoscience and related nanotechnology, thereby spreading awareness all over the globe and promoting anticipated trends in the field of nanoscience and nanotechnology. The major objective of this initiative is to bring all the fundamental concepts, target delivery, herbal bioactive, and nanomedicine, all in a common platform that will provide knowledge about all the possible advanced pharmaceutical, herbal nanoscience drug delivery systems. Some major chapters to be published in the book include nucleic acid-based therapeutic, electrosomes, aquasomes, phytosomes, guggulosome, niosomes, self nano/micro emulsified drug delivery system, the concept of targeted drug delivery system, application of herbal Bioactive and many more. This valuable resource will make the readers more aware of novel drug delivery systems as well as their promising applications in drug targeting and nanotheronostics, thereby improving the pharmaceutical world's situation.

The book's aim is to provide a single volume covering a detailed description of various herbal drug delivery systems, their principles and how these are put in use for the treatment of vivid diseases. The book has been divided into four sections. The first section deals with the fundamentals of advanced pharmaceutical nanoscience, whereas the second section deals with a detailed overview of the novel and efficient advanced pharmaceutical nanoscience delivery systems in the field of pharmaceutical science in which some major topics will be published in the book, which includes nucleic acid-based therapeutic, electrosomes, aquasomes, phytosomes, guggulosome, niosomes, self nano/micro emulsified drug, *etc.* This section is quite unique as it elaborately describes the major main beliefs and techniques of the preparations of the herbal drug delivery systems. This furnishes a quite unique and updated coverage of the essential areas that guide the underlying science behind these therapeutic delivery systems. The distinguished authors have emphasized on providing a complete insight into the advanced pharmaceutical nanoscience drug delivery systems with their convenient applications in the field of herbal nanoscience technology. The third section mainly involves diseases specific to advanced pharmaceutical nanoscience targeted drug delivery systems like cancer, infectious



diseases, brain diseases, *etc.* Finally, the fourth and the last section of the book provides the application of herbal bioactive in pharmaceutical, herbal nanoscience targeted drug delivery systems.

This advanced book has been designed keeping in mind the young and new researchers and scientists who are working dedicatedly in the field of health/medicine and the pharmaceutical sector. This book promises a detailed, informative description of advanced herbal and absolutely modern pharmaceutical dosage forms and drug delivery systems. The information furnished in the book is sure to serve society.



**Dr. Swarnlata Saraf**  
Professor & Director University Institute of Pharmacy  
Pt Ravishankar Shukla University  
Raipur-492010, Chhattisgarh, India



**Dr. Ram Kumar Sahu**  
Assistant Professor, Department of Pharmaceutical Science  
Sushruta School of Medical and Paramedical Sciences  
Assam University (A Central University)  
Silchar-788011, Assam, India



**Dr. Vivek Dave**  
Associate Professor & Head, Department of Pharmacy  
School of Health Science Central University of South Bihar  
Bihar -824236, India

## List of Contributors

<b>Andang Miatmoko</b>	Department of Pharmaceutical Science, Faculty of Pharmacy, Universitas Airlangga, Surabaya, 60115, Indonesia
<b>Ankit Jain</b>	Department of Material Engineering, IISC, Bangalore, India
<b>Arun Kumar</b>	Department of Chemistry, Department of Pharmaceutical Science, Gurukul Kangri (Deemed to be University), Haridwar, Uttarakhand, India
<b>Claire Faye C. Zipagan</b>	Graduate School, Centro Escolar University, Manila, Philippines Cognizant Technology Solutions, Taguig City, Philippines Pharmacy Department, San Pedro College, Davao City, Philippines
<b>Devy Maulidya Cahyani</b>	Department of Pharmaceutical Science, Faculty of Pharmacy, Universitas Airlangga, Surabaya, 60115, Indonesia
<b>Erwin Martinez Faller</b>	School of Pharmacy, San Pedro College, Philippines/Graduate School, Centro Escolar University, Manila, Philippines
<b>Jaya Dwivedi</b>	Department of Chemistry, Banasthali Vidyapith, Banasthali, P.O. Rajasthan-304022, India
<b>Jiyauddin Khan</b>	School of Pharmacy, Management and Science University, 40100 Shah Alam, Selangor, Malaysia
<b>Kenny Shane P.</b>	Alojado, Graduate School, Centro Escolar University, Manila, Philippines
<b>Maria Maichol P.</b>	Ababan, Graduate School, Centro Escolar University, Manila, Philippines
<b>Mayank Kumar Malik</b>	KIET School of Pharmacy, KIET Group of Institutions, Muradnagar, Ghaziabad, U.P, India
<b>Nagaraja Sreeharsha</b>	Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa-31982, Saudi Arabia Department of Pharmaceutics, Vidya Siri College of Pharmacy, Off Sarjapura Road, Bengaluru - 560 035, Karnataka, India
<b>Pankaj Bhatt</b>	Department of Pharmaceutical Science, Gurukul Kangri (Deemed to be University), Haridwar, Uttarakhand, India
<b>Payal Kesharwani</b>	Department of Pharmacy, Banasthali Vidyapith, Banasthali, India
<b>Prashansa Sharma</b>	Department of Home Science, Mahila Mahavidyalaya, Banaras Hindu University, India
<b>Priya Shrivastava</b>	Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H. S. Gour Vishwavidyalaya, Sagar, M.P., 470003, India
<b>Priyanka Soni</b>	Department of Herbal Drug Research, B.R. Nahata College of Pharmacy, Research Centre, Mhow Neemuch Road, Mandsaur 458001, India
<b>Rajeev Sharma</b>	Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H. S. Gour Vishwavidyalaya, Sagar, M.P., 470003, India
<b>Ram Kumar Sahu</b>	Department of Pharmaceutical Sciences, Sushruta School of Medical and Paramedical Sciences, Assam University (A Central University), Silchar-788011, Assam, India
<b>Retno Widjowati</b>	Department of Pharmaceutical Science, Faculty of Pharmacy, Universitas Airlangga, Surabaya, 60115, Indonesia Natural Product Drug Discovery and Development Research Group, Faculty of Pharmacy, Universitas Airlangga, Surabaya 60115, Indonesia

<b>Ritika Gururani</b>	Department of Pharmacy, Banasthali Vidyapith, Banasthali, P.O. Rajasthan-304022, India
<b>S. P. Vyas</b>	Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H. S. Gour Vishwavidyalaya, Sagar, M.P., 470003, India
<b>Santosh Fattepur</b>	School of Pharmacy, Management and Science University, Seksyen 13, 40100 Shah Alam, Selangor, Malaysia
<b>Smita Jain</b>	Department of Pharmacy, Banasthali Vidyapith, Banasthali, India
<b>Srija Sur</b>	School of Pharmaceutical Technology, Adamas University, India
<b>Swapnil Sharma</b>	Department of Pharmacy, Banasthali Vidyapith, Banasthali, P.O. Rajasthan-304022, India
<b>Udita Agrawal</b>	Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. H. S. Gour Vishwavidyalaya, Sagar, M.P., 470003, India
<b>Vipin Kumar</b>	Department of Pharmaceutical Science, Gurukul Kangri (Deemed to be University), Haridwar, Uttarakhand, India
<b>Vinod Nautiyal</b>	Department of Pharmaceutical Sciences, Gurukul Kangri University Haridwar, Uttarakhand, India
<b>Vishal Soni</b>	Department of Herbal Drug Research, B.R. Nahata College of Pharmacy, Research Centre, Mhow Neemuch Road, Mandsaur 458 001, India
<b>Vishal Trivedi</b>	Department of Pharmacy, Madhav University, Abu Road, Pindwara, Rajasthan, India
<b>Vivek Dave</b>	Department of Pharmacy, School of Health Science Central University of South Bihar, Bihar -824236, India

---

**CHAPTER 1**

---

**Pharmaceutical Nanosciences and their Application in the Delivery of Various Phytoconstituents****Retno Widyowati<sup>1,2,\*</sup> and Andang Miatmoko<sup>1</sup>**<sup>1</sup> *Department of Pharmaceutical Science, Faculty of Pharmacy, Universitas Airlangga, Surabaya, 60115, Indonesia*<sup>2</sup> *Natural Product Drug Discovery and Development Research Group, Faculty of Pharmacy, Universitas Airlangga, Surabaya, 60115, Indonesia*

**Abstract:** Nanoscience provides numerous opportunities for pharmaceutical scientists. Due to the continuing progress of nanoparticle-based medicines, the opportunity to treat and combat difficult diseases, especially with herbal remedies, can be achieved. The use of herbs is effective when their active constituents reach the intended target. However, the flavonoids, tannins, and terpenoids present in herbs are hydrophilic and unable to pass through cell lipid membranes. Therefore, their absorption is poor, resulting in reduced availability and biological efficacy, increased dosage, and frequency of use. Nanoengineering has verified that nanoparticles have significant potential as drug carriers. Size reduction methods and technologies produce a wide variety of nanostructures, which are indicative of specific physicochemical and biological properties. This delivery system plays an essential role in increasing the solubility, bioavailability, pharmacological effect, stability, effectiveness, selectivity, and drug specificity of its bioactive constituents. Nanoscale models such as phytosomes, liposomes, nanoemulsions, nanoparticles, solid lipid nanoparticles, and ethosomes are used to deliver various bioactive constituents at adequate doses to the target during the entire treatment period. Phospholipid complex techniques have recently been introduced to overcome these barriers either by enhancing their dissolving capacity or their potential ability to traverse biological membranes and protect the active herbal constituents against degradation. Therefore, this chapter discusses the application of nanoscience for delivering various phytoconstituents in order to achieve therapeutic targets.

**Keywords:** Herbal medicine, Nanotechnology, Phytoconstituents.

---

\* **Corresponding author Retno Widyowati:** Department of Pharmaceutical Science, Faculty of Pharmacy, Universitas Airlangga, Surabaya, 60115, Indonesia; E-mail: rr-retno-w@ff.unair.ac.id and Natural Product Drug Discovery and Development Research Group, Faculty of Pharmacy, Universitas Airlangga, Surabaya, 60115, Indonesia

## **INTRODUCTION**

Nanotechnology is a science that changes the dimensions of matter at the nanoscale level. Recently, this branch of science has been indispensable to the pharmaceutical and drug industries because of its potential to play a crucial role in improving human life. These scientific applications are related to the medical field and include the therapeutic applications of drug delivery, enhancing drug efficacy, reducing side effects, and improving circulation and stability [1]. The majority of phytoconstituents are declared active if they are proven to have a confirmed impact on the treatment of specific diseases or pain relief and are classified as organic constituents. The active organic constituents demonstrate low bioavailability while being predominantly non-water soluble, unstable, and the most toxic.

Nanoparticles are frequently used as therapeutic and diagnostic agents because of their advanced and essential drug delivery systems. For example, materials incorporating protein or nucleic acids require a carrier system that potentially enhances their effectiveness and shields them from undesired degradation [2]. The potency of the drug nanoparticle delivery system is directly associated with its small particles and huge surface area, thus indicating increased solubility and the capacity to pass through the blood-brain barrier (BBB), enter the respiratory system, and be captivated across the close connections of skin epithelial tissue cells [3].

Formulations based on herbal medicines or their active phytoconstituents remain subjected to numerous limitations [4]. Nevertheless, they are considered a major source because of their less severe side effects compared to those of synthetic drugs and the deep-seated public belief in their ability to cure or prevent various diseases. Several methods are employed to overcome these limitations, including dissolving in non-polar solvents, making injection preparations, and increasing their solubility by changing the active phytoconstituents into their salt form. These methods have several drawbacks, such as high solvent toxicity, their uncertain activity when in salt form, the presence of bioactive drug forms, and the lack of bioavailability. Consequently, special technology, namely nanotechnology, needs to be employed as a solution. With the application of nanotechnology, herbal medicines can deliver their active phytoconstituents to specific targets. These nanoparticle techniques are designed and delivered with various sizes, forms, compositions, functions, and physical/chemical modifications to suit the distinctiveness of the targeted organs and the specific drug used. The dosage forms of nanoparticles include fullerenes, emulsions, microemulsions, liposomes, liquid crystals, dendrimers, quantum dots, nanoparticles, gels, solid lipid nanoparticles, among others. This chapter will,

therefore, briefly focus on herbal medicine nanoparticles to overcome several formulation deficiencies associated with phytoconstituents in herbs.

## **PHYTOCONSTITUENTS IN HERBAL MEDICINE**

Phytoconstituents found in herbs are commonly referred to as secondary metabolites, namely phenolics, terpenoids, alkaloids, and anthraquinones. These compounds have high curative value, but their bioavailability and solubility are low, while their toxicity and instability may hinder their medicinal use [5].

### **Phenolic**

Almost all plants contain phenolic compounds which are aromatic in character and contain more than one hydroxyl substituent. The main compounds are phenols, many of which are found in polyphenols, and among which more than 8,000 compounds have been identified. Based on their primary chemical structures, polyphenols are divided into stilbenes, phenolic acids, flavonoids, and lignans. Flavonoids are one of the naturally occurring polyphenols, with more than 6,000 compounds being identified. They include flavones, flavonols, flavans, flavanones, dihydroflavanols, isoflavons, and biflavones [6]. Compounds within this class execute a protective function against free radicals, cardiovascular disease, cancer, inflammation, microbial contamination, viruses, allergies, and ulcers, among other diseases [7]. Other phenolic compounds include quinones, xanthenes, coumarins, polymer lignins, and tannins. Phenylpropanoid dimers or lignans containing two C6-C3 bound by C-8 carbon centres have antiviral, anticancer, anti-inflammatory, antimicrobial, antioxidant, immunosuppressive, and hepatoprotective properties and are used in osteoporosis prevention [8].

Polyphenols have properties that are challenging to address due to the presence of several phenyl rings in the compound, the number of hydroxyl groups in the aromatic cycle, and the bioavailability of polyphenols in food that depends on pre- and post-harvest conditions and interactions with other compounds. Since these class compounds demonstrate extremely limited absorption ability, poor solubility in water, and rapid metabolism, they need to be made into several types of pharmaceutical formulations with the potential to increase bioavailability. Certain polyphenols have low stability and, therefore, selecting the liposome form for polyphenol encapsulation is considered appropriate. However, it is also important to note the characteristics of each polyphenol, which have various molecular structures within which the ring and hydroxyl numbers affect their solubility [7]. One example is that of a podophyllotoxin employed as an anti-mitotic whose high toxicity limits its use [9]. To overcome this problem, modification of the podophyllotoxin structure is undertaken in the hope that its toxicity will be reduced.

Resveratrol is a polyphenol compound contained in *Vitis vinifera*, labrusca, and muscadine [10], which possesses anti-oxidant, anti-cancer, anti-inflammatory, and cardioprotective properties [11]. Due to being moderately water-soluble, resveratrol demonstrates full bioavailability, photosensitivity [12], and rapid metabolism [13]. Multiple nanoencapsulation of resveratrol, polymer nanoparticles, Zein-based nanoparticles, nanoemulsions, liposomes, cyclodextrins, and resveratrol have been reported to enhance bioavailability and pharmacokinetics [14 - 19]. The polyphenol will improve solubility and chemical stability if formulated with dipalmytoyl-phosphatidylcholine or distearoyl-phosphatidylethanolamine-polyethylene glycol 2000. It also prolongs efficacy and improves protection from UV B when combined with P90G or dicetyl phosphate [7].

Curcumin (diferuloyl-methane) is moderately soluble in water, has low bioavailability and is produced in the formulation of liposomes, phospholipid vesicles, and polymer-based nano formulations [20, 21]. Oral bioavailability is nine times higher when curcumin is combined with piperine, which functions as an absorption enhancer [22]. In addition, curcumin colloid nanoparticles (theracurmin) are 27 times more effective and can inhibit alcohol poisoning [23]. Curcumin formulated in liposomes using soybean phosphatidylcholine, film hydration, and extrusion (MLV) will prolong the antioxidant protective effect. On the other hand, when formulated using dimyristoyl phosphatidylglycerol and lyophilisate, it enhances the bioavailability while reducing the incidence of protease cancer and exerting an antiangiogenic effect [7].

Quercetin, a natural flavonoid in various vegetables and fruits, is 100 times more water-soluble after being formulated as a polymer nanoparticle suspension dosage form [24]. Ampelopsin, produced from *Ampelopsis grossedentata*, has anti-oxidant, anti-inflammatory, anti-hypertensive, anti-microbial, hepatoprotective, anti-carcinogenic properties, and cough-relieving effects. This compound is moderately water-soluble with very low permeability and is consequently packaged in microemulsions to increase bioavailability, solubility, and penetration [25]. Quercetin is formed in liposomes using dipalmytoyl-phosphatidylcholine and lecithin that increases solubility, bioavailability, and anti-tumor and antioxidant properties [7]. *Origanum dictamnus* extract contains anti-oxidant and anti-microbial substances due to large amounts of coumarin and flavones, which are formed into liposomes to increase their activity [26].

Encapsulation, which protects phytoconstituents, can be used to reduce the instability of the active ingredient, retard its degradation, and increase activity. For example, quercetin formed in liposomes with PEG in plasma has a life span exceeding five hours [27], whereas quercetin formulated in polymer nanoparticles

form demonstrates increased anti-oxidant activity, while quercetin encapsulated in Eudragite nanoparticles (polymer nanoparticles) is very stable [28].

Certain other polyphenols, such as catechin, fisetin, dehydro-silymarin, and silymarin, increase bioavailability, solubility, chemical stability, while several activities in liposome form use epikuron/Tween, dioleoyl phosphatidylcholine/PEG 2000, soybean phosphatidylcholine, lecithin, and mannitol [7].

The application of a lipid bilayer in liposomes increases catechin permeability. It occurs because of the geometric relationship between lipids in liposomes and insoluble encapsulation drugs (catechins) [7]. To date, no system has generalized the composition and encapsulation of lipids. A significant body of research has concentrated on the modification of liposome surfaces and their composition in enhancing the incorporation of insoluble drugs and well-defined target locations.

### Terpenoid

Terpenoids represent the most widespread group of natural compounds, with more than 40,000 having been identified so far. In general, the structure of terpenes is formed from isoprene units with its constituent groups in the form of cyclic unsaturated hydrocarbons at varying degrees of oxygen. Terpenoids are grouped on the basis of the number of isoprene units; monoterpenes (one isoprene), sesquiterpenes, diterpenes (two isoprenes), triterpenes (three isoprenes), and tetraterpenes (four isoprenes). A variety of terpenoids have been found to have anti-cancer, anti-alzheimer [29], anti-microbial, anti-fungal, anti-parasitic, anti-allergic, anti-spasmodic, anti-hyperglycemic, anti-inflammatory, and immunomodulatory properties [30].

Monoterpenes constitute the main class of terpenoids that contain one isoprene unit found in floral aromas, plants containing essential oils, and aromatic plant resins [31], which act as anti-tumor agents. Thymoquinone is an active anti-oxidant, anti-inflammatory, and anti-cancer constituent of *Nigella sativa* [32, 33]. However, the compounds have limitations, such as poor solubility, extreme lipophilicity, and light and heat-instability that hinder pharmaceutical applications. Triterpenoids have more than 90 carbon skeletons with oxidative modification and skeleton glycosidation resulting in greater diversity [34]. Ursolic acid (UA) and oleanolic acid (OA) are natural triterpenoids obtained from no less than 120 plants. OA has hepatoprotective, anti-inflammatory, anti-hyperlipidemic, anti-tumor, and anti-viral qualities, whereas UA has anti-inflammatory, anti-hyperlipidemic, anti-hyperglycemic, hepatoprotective, anti-carcinogenic, neuroprotective, and anti-ulcer properties [35]. Their bioavailability is severely restricted by an extremely limited solubility in water.



Cucurbitacins are bitter, toxic, oxidized tetracyclic triterpenoids. These compounds can be obtained from the Rubiaceae, Cucurbitaceae, Desfontainiaceae, Scrophulariaceae, Begoniaceae, Elaeocarpaceae, Polemoniaceae, Thymelaeaceae, Primulaceae, Brassicaceae, Sterculiaceae, Datisceae, and Rosaceae families. These compounds function as heterologous chemical secretions that protect plants from external biological threats [36], and their anti-pyretic, anti-inflammatory, anti-tumor, anti-microbial, and analgesic characteristics are useful [37].

Triptolide is an epoxide diterpenoid isolated from *Tripterygium wilfordii* and useful in treating polycystic kidney diseases, pancreatic carcinoma, autoimmune, rheumatism, leukemia, and psoriasis even though this compound demonstrates poor solubility and high toxicity. Triptolide is prepared in a microemulsion system as poly [DL-lactic acid] [38] nanoparticles, which are biocompatible and biodegradable for transdermal preparations. Since one side effect of Triptolide is irritation of the gastric system, it is encapsulated in SLN to minimize this effect [39].

Cryptotanshinone is a member of the quinoid diterpene class contained in the root of *Salvia miltiorrhiza* Bunge and has applications as an anti-inflammatory, anti-bacterial, cytotoxic, anti-oxidative, anti-angiogenic and anti-parasitic, but has poor bioavailability due to water solubility. The bioavailability of cryptotanshinone administered orally will increase when prepared in solid nano lipid formulation [40].

Thymoquinone is a monoterpene extracted from *Nigella sativa* seeds that have anticancer properties [41], poor solubility, and strong hydrophobicity. The preparation of an encapsulating thymoquinone formula with polymers [42], liposomes [43], and cyclo-dextrin [44] can overcome this problem.

### **Alkaloid**

The structural framework for alkaloids containing nitrogen atoms as part of the heterocyclic ring structure supports significant biological activity, for example, ephedrine for asthma, morphine for analgesics, and vinblastine as an anticancer treatment. The alkaloids, vinblastine, vincristine, and vinorelbine disrupt the microtubule network, causing metaphase capture in dividing cells [45], allowing for the preparation of a controlled release formulation that would endure for a long time. However, these compounds have side effects that include hematological toxicity, wheezing, dyspnea, vomiting, nausea, constipation, fever, chest pain, and tumors. Investigators have recently reported that the application of liposome nanocarrier preparations of vinca alkaloids alleviates these side effects [45, 46].

Tetrandrine is a bis-benzylisoquinoline alkaloid that induces anti-tumor activity and constitutes a non-selective calcium channel blocker. Since this compound has poor water solubility, its incorporation into the SLN system [47] can improve the formula. Paclitaxel in the gelatin nanoparticle formula is an extremely effective treatment for bladder cancer because the release rate of the active ingredient and its solubility in aqueous media becomes easier [38]. This active ingredient has been certified by the FDA as an effective and non-toxic cancer treatment marketed under the tradename Abraxane.

Anabasine is a piperidine alkaloid derived from the highly toxic *Nicotiana glauca* tree but whose toxicity decreases after formulation with supramolecular nano-encapsulation [48]. Trigonelin is introduced into the chitosan nanoparticles through the formation of an ion complex between the trigonelin's anionic carboxylic acid group and the chitosan cationic amine group to form particles less than 500 nm in size, which inhibit tumor cell invasion [49].

The Epiisopiloturine in *Jaborandi epiisopiloturine* leaves affects adult and young *Schistosoma mansoni* in addition to their eggs and is difficult to dissolve. Therefore, the structure of the liposomes is induced to increase solubility through the addition of dipalmitoylphosphatidylcholine (DPPC)/cholesterol.

### **Anthraquinone**

Anthraquinone constitutes a group of secondary metabolite compounds that occur in abundance in natural materials. Anthraquinones are quinone derivatives of anthracenes with a basic structure of 9,10-anthraquinone dicetone. The presence of methoxyl, methyl, hydroxyl, and carboxyl groups attached to the core structure of 9,10-anthracenedione produces anthraquinone derivatives, which have a wide spectrum of medicinal properties [50].

This group contains the largest number of natural pigments, including 700 compounds, 200 of which are isolated from plants (roots, rhizomes, fruits, and flowers), while the rest are derived from mosses and fungi [51]. They are widely employed due to their anti-tumor, anti-inflammatory, diuretic, antiarthritic, antifungal, antibacterial, antimalarial, antioxidant, and laxative properties [52].

Hypericin, a naphthodianthrone (anthraquinone) compound that is a natural photosensitizer, demonstrates high hydrophobicity but limited solubility. The formulation of hypericin solid lipid nanoparticle (Hy-SLN) and the hypericin polymeric nanoparticle suspension is evolved to acquire preferable photodynamic and photoprotection [53].

Photodynamic therapy has many drawbacks, including poor water solubility and photosensitizer drug toxicity; thus anthraquinone derivatives derived from biotechnology and prepared classic nanocapsule formulations containing polycoating (PLGA) are capable of increasing photosensitizer cell uptake while also being non-toxic [54].

Radix rhei contains less efficient rhein, chrysophanol, physcione, emodin, and aloemodin. These compounds are formulated in the form of liposomes by ethanol injection method with the result that the entrapment efficiency of the liposomal encapsulation is high [55].

### **NANOTECH FOR THE DELIVERY OF DIFFERENT PHYTOCONSTITUENTS**

The problems faced with regard to herbal formulations are those of moderate solubility in water, poor bioavailability, instability, and toxicity. Nanotechnology is effective in overcoming a number of the difficulties arising from the use of both synthetic and natural drug molecules. This technology has produced acceptable formulas, such as embedded active phytochemicals. Various nanoparticle systems such as encapsulation in the nanocarrier system and the deliverance of active compounds have been applied to support formulations. The different kinds of nanoparticles are dendrimers, solid lipid nanoparticles, liposomes, inorganic nanoparticles, microemulsions, polymer nanoparticles, and nanoflora, among others. This combination of technologies is able to achieve the last stage of active compound examination, thus enhancing the healthcare system.

Nano/submicro medicines ranging in size from 1 to 1000 nm, including liposomes, microspheres, solid lipid nanoparticles, nanoemulsions, and microemulsions (Fig. 1), are frequently employed as herbal medicines, both topically and systemically [56]. This system features controlled hydrophobic and hydrophilic drug delivery, high drug-carrying capacity, superior stability [56, 57], higher surface area proportional to volume [57, 58], and has a small size that supports high skin interactions, increases skin penetration and extends the turnover number of molecules to the targeted sites through active targeting [57,59,60]. Numerous nanoparticle systems composed of biodegradable and biocompatible materials can be applied to encase toxic drugs and transport them to specific sites around the body.




Fig. (1). Overview of nano/sub-microcarriers in herbal medicine [59].

## Liposome

Liposomes are tiny vesicles consisting of one or more concentric lipid bilayers (phospholipids) between which an aqueous medium is present. The name ‘liposome’ is derived from the Greek terms, ‘lipo’, which means ‘fat’ and ‘soma,’ which translates as ‘body.’ Therefore, liposomes are described as round objects which are predominantly composed of lipids. Liposomes are categorized as cationic, neutral, or anionic because of their type of surface charge. Variations in shape, size and amount of lamellae contained in liposomes lead to their respective classification as unilamellar liposomes (ULs), small unilamellar vesicles (SUV, 25–100 nm), multilamellar vesicles (MLV), large unilamellar vesicles (LUV, 100 nm to 1 μm), multivesicular vesicles (MVV). Liposomes are easily produced by disrupting the lipid membrane in an aqueous medium through a sequence of extrusion (sonication) processes combined with a freezing-thaw process.

Liposomes demonstrate strong biocompatibility and can improve physicochemical characteristics in pursuance of their lipid contexture and value. Vesicles are obtained from natural phospholipids that surround the water core. Liposomes are capable of trapping both hydrophilic and lipophilic medications in the aqueous phase and lipidic bilayer with the result that lipophilic drugs will be highly efficient given the integrity of the membrane bilayer [33]. Plants and phytoconstituents that have been formulated using a liposome system can be seen in Table 1.

**Table 1. Liposome in several plants [4].**

Plants	Carrier system	Methods	Effects
Cratylia mollis lectin	Soybean-phosphatidylcholine, cholesterol, and stearylamine	Positively charged surfaces	Degraded toxicity and escalated antitumor activity
Quercetin	Egg phosphatidylcholine & cholesterol	Negatively charged surfaces	Efficiency is between 60%–80%
Silymarin	Lecithin and cholesterol	Reverse evaporation	Improved bioavailability and absorption
Breviscapine	Phosphatidylcholine, cholesterol, phosphatidylglycerol and triolein/tricaprylin	Double emulsification	Prolonged sustained delivery
Camptothecin	3.5-bis (dodecyloxy) benzoic (PO)-polyethylene glycol	Coating the surface	More efficient
<i>A. arborescens</i> essential oil	Hydrogenated and non-hydrogenated soy phosphatidylcholine	Positively charged MLVs and SUVs	A great ability to entice EO (60%-74%)

Liposomes play an important role as a drug carrier system because they can encapsulate polar and non-polar compounds, are stable, have a lengthy shelf life, are manageable, and their biocompatibility and degradability can be regulated. Specific disadvantages of liposomes are their short half-lives and their vesicle integrity being unsuitable for non-polar drugs. Phytosomes are phospholipids of nanoparticles covalently attached to phytochemicals [61].

Liposomes are flexible because they have a lipid structure that can be adjusted to drugs and a surface that can be converted for a specific target and time. The composition is adjusted to increase drug solubility within the encapsulation system [7].

### Microemulsion

Microemulsion (ME) constitutes a fluid system consisting of a simple, transparent emulsion with alcohol or medium chains (hexanol, pentanol) dissolved in an aqueous medium and including surfactants produced by the titration method. The presence of surfactants makes the system conditions thermodynamically stable with internal phase droplets at the nanoscale (10-100 nm). The active ingredients in the ME system will become distinct from the dispersion medium *via* the membrane or interface and transferred to an environment that can improve solubility, modular stability, and bioavailability profile. The increased solubility and stability of ME are capable of delivering active constituents with different levels of lipophilic/hydrophilicity in the same formulation [62].

An example of the use of microemulsions is that of the triptolide compound contained in the vine *Tripterygium wilfordii* Hook. F (Celastraceae). This plant has anti-inflammatory, anti-neoplastic, anti-fertility, and immunosuppressive properties, but its water solubility is very poor, and it is toxic. It is formulated in isopropyl myristate TP as oil phase, aqueous water phase, and Tween 80: 1,2-propylene glycol as surfactant: co-surfactant in order to increase the permeation profile and anti-inflammatory test [63]. In addition, *Syagrus romanzoffiana* (Cham.) Glassman (Arecaceae) pulp extract is formulated in an o/w nanoemulsion system with squalane as an oil phase and a couple of ethoxylated surfactants with oleic alcohol as non-ionic surfactant, which can increase its antioxidant activity.

### **Solid Lipid Nanoparticles and Nanostructured Lipid Carriers**

Solid lipid nanoparticles (SLN) are colloid vehicle systems (50–1,000 nm) containing pure triglycerides and are combined with other colloid systems (emulsions, liposomes, and polymer nanoparticles) to eliminate shortages of active ingredients [64]. SLN has high physicochemical stability and provides protection against the degradation caused by labile drugs [65]. The resulting structures of this system are solid lipids or mixtures, which are stabilized by surfactants [66].

The nanostructured lipid carrier (NLC) is a colloid system that comprises a lipid and solid-phase mixture to form an irregular liquid lipid matrix, increase the encapsulation efficiency, and minimize the active particle excretion during encapsulation [67]. The solid lipid phases of the NLC system feature glyceryl dilauric, stearic acid, hydrine, cetyl alcohol, and glyceryl monostearate, while the liquid phases involve caprylic/capric acid, oleic acid, and glyceryl monodicaprylic. Generally, the manufacture of NLC systems requires 5% of the active ingredient to form part of the initial precursor mixture in order to produce a drug efficiency of approximately 3%-4% orally and 70% topically [68].

The methods of SLN and NLC formulation include high-pressure homogenization (HPH), emulsification-sonification, microemulsions, and solvent evaporation-emulsification techniques.

- HPH method involves melting the lipids so that the medicine is homogeneously dispersed in the liquid lipid. It is subsequently added to the hot surfactant solution and homogeneously dispersed (pre-emulsified) by means of a sharp mixer. The nanoemulsion is then cooled at room temperature to form crystals. The cold HPH method is the same as its hot counterpart, but the crystallization process uses liquid nitrogen, rendering this technique safe for hydrophilic or thermolabile drugs.

- The emulsification-sonification method involves dissolving the active ingredient in a thawed solid lipid, adding a warm water surfactant solution, and, finally, dispersing it homogeneously using a high shear mixer. The oil emulsion formed is separated using a sonicator probe according to the nanoemulsion size and then cooled.
- The microemulsion method dissolves the active ingredient in solid lipid and aqueous surfactant/cosurfactant solution that is added during light agitation to produce a clear microemulsion. It is then dissolved in cold water (2-10°C) through light agitation and immediately crystallized to form SLN.
- The solvent-evaporation-emulsifying method works by dissolving lipids in an organic solvent, such as chloroform/cyclohexane, and emulsifying them with aqueous surfactants under continuous stirring.

The results of the utilization of nanostructured lipid carriers and solid lipid nanoparticles in several plants are mentioned in Table 2.

**Table 2. Nanostructured Lipid Carriers and Solid Lipid Nanoparticles in several plants [4].**

Constituents	SLN/NLC formulation	Methods	Effects
Quercetin	SLNs (glyceryl monostearate, & soy lecithin)	Emulsification-sonification	Controlled release, increases bioavailability fivefold and enhances absorption within the intestines
	SLNs (glyceryl dibehenate & oleic acid)	Microemulsification	Increases efficiency (92.33%), stability and oral bioavailability
	NLCs (glyceryl monostearate, stearic acid, & soy lecithin)	Emulsion evaporation-sonification	Promotes permeation, increases the number of substances that resist in both epidermis and dermis, and enhances anti-inflammatory and anti-oxidant activities
	NLCs	Probe ultrasonication	Excellent stability
Triptolide ( <i>Tripterygium wilfordii</i> )	SLNs (tristearin glyceride & stearic acid)	Microemulsification	Improves solubility and absorption into the skin.
Camptothecin	SLNs (cetyl palmitate & polysorbate 80)	Microemulsification	Increases bioavailability
Curcuminoid	SLNs (stearic acid and glyceryl monostearate)	Microemulsification	Improves stability

## Inorganic Nanoparticles

Inorganic nanoparticles are present in inorganic compounds such as ceramics, silver, carbon, and gold. These systems are classified as follows:

- Transition metal nanoparticles (Au, Ti, Pt)  
Transition metals serve as medications in cases where excitation by a radiance occurs, which damages DNA and/or modifies proteins, increases lipid peroxidation, and destroys the cell microenvironment causing death. This method can be utilized for the treatment of cancer, carriers of site-specific toxic drugs [69], and potent catalysts.
- Ceramic nanoparticles (oxides, nitrides, and carbides with silica)  
The system can be used as a hollow or core-shell coated with a biodegradable and biocompatible polymer that enhances targeted delivery properties.
- Carbon nanoparticles.

## Liquid Crystalline Systems

Liquid crystal (LC) is a distinct phase between crystalline solid and isotropic liquid (mesophase) in the condensed structure. Mesophases, being cubic or hexagonal, are classified into lyotropic liquid crystals (LLCs) and thermotropic liquid crystals (TLC) [70]. TLC is a mesophase molecule that requires a specific temperature to be converted into an isotropic liquid. On the other hand, LLC is an amphiphilic molecule micelle with a tiny polar oxtail (hydrophilic) and a large apolar oxtail (hydrophobic). Mesophase can be identified using low-angle X-ray scattering (SAXS), low-angle neutron scattering (SANS), cryofracture electron microscopy, neutron diffraction, and reflected light microscopy [71].

LC application of herbal medicine is highly advantageous because it is stable, and interacts easily and optimally with specific targets to create a reliable, effective, and safe drug delivery system, whose distribution is even with the selected administration route and has minor side effects [72]. Vegetable oil is the most useful plant component for the development of this LC system because of its low molecular weight and poor viscosity. Vegetable oils produce low occlusion leading to their easy penetration in the skin and increased loading of therapeutic agents [73].

Santos and Rocha-Filho proved the effect of carbon bond length and the number of ethylene oxide groups on the stability of the nonionic emulsion in vegetable oils and recommended the use of such oils derived from apricot (*Prunus armeniaca*), pequi (*Caryocar brasiliense*), avocado (*Persea americana*), cupuassu (*Theobroma grandiflorum*), Brazil nuts (*Bertholletia excelsa*), mari-gold (*C. officinalis*),



andiroba (*Carapa guyanensis*), passion fruit (*Passiflora edulis*), and Buriti (*Mauritia flexuosa*). For the LC lamellar crystal stage, polyoxyethylene stearyl ether (Steareth-2; HLB: 4.7) and polyoxyethylene cetyl stearyl ether (Cetareth-5; HLB: 9.2) acted as surfactants and distilled water as the waterphase. Liquid crystal systems can be used to overcome formulation limitations in plants and phytoconstituents (Table 3).

**Table 3. Liquid crystalline systems in several plants [4].**

Plants	Carrier System	Methods	Effects
Andiroba ( <i>Carapa guyanensis</i> Aubl.)	<ul style="list-style-type: none"> <li>• Oily phase: dicetyl phosphate, cetearyl alcohol, ceteth-10 phosphate</li> <li>• Aqueous phase: distilled water &amp; PEG-12 Dimethicone</li> </ul>	Silicone (surfactant)	Formulation viscosity, or rheological stability
Peach essential oil ( <i>Prunus persica</i> )	LCs	Oil in water emulsions (o/w)	Improve physical stability
Annatto oil ( <i>Bixa orellana</i> )	<ul style="list-style-type: none"> <li>• Aqueous phase: Distilled water</li> <li>• Surfactant: oleth-20</li> </ul>	Hydrophilic/lipophilic balance (HLB)	Constructs LC
Marigold oil ( <i>Calendula officinalis</i> )	<ul style="list-style-type: none"> <li>• Aqueous phase: Distilled water</li> <li>• Surfactant: nonionic</li> </ul>	HLB	Stable formulation
Marigold oil ( <i>C. officinalis</i> )	<ul style="list-style-type: none"> <li>• Aqueous phase: Distilled water</li> <li>• Surfactant: polyoxyethylene alkyl/stearyl ethers</li> </ul>	Lamellar LC phases	Stability

## POLYMER NANOPARTICLES

Polymer nanoparticles are polymer-based formulations whose biodegradability and biocompatibility render them suitable as drug delivery systems because they are easy to control and target [74]. The colloid system of nanoparticles acts as a vector to manage the drug delivery and target it on a specific location. This system can escalate constituent solubility, reduce the therapeutic dose, and improve the absorption of its active components. This system can be applied to the blood because it involves non-activate neutrophils, is steady, non-immunogenic, non-toxic, non-thrombogenic, non-inflammatory, and avoids the reticuloendothelial route. Natural ingredients are produced in this system because of their ability to provide several active compounds with a similar carrier, supply a continuous delivery system, and reduce side effects.

Polymer nanoparticles fall within a diameter scale of 10–1,000 nm to facilitate the release of active substances to the target, increase bioavailability, and mitigate side effects [75]. The shape of the nanoparticles is differentiated according to their composition and structural organization in the form of nanocapsules (NCs) and

nanospheres (NSs). NCs have an oil core and are encased in a polymeric membrane which soaks up the active constituents before they are dispersed throughout the oil base. NSs have a polymer structure that retains or absorbs the active ingredients. The types of polymers widely applied are copolymers with glycolic acid (PLGA) and poly-L-lactic acid (PLA) [76].

The polymer nanoparticle method is categorized as a dispersed monomer method using alkyl cyanoacrylate, *in situ* polymerization method, and polymer deposition methods using polylactic acid-co-glycolic/PLGA, acrylic/methacrylate esters, poly-caprolactone/PCL, polylactic acid/PLA, and methacrylic acid copolymers (Table 4). The product obtained through the application of these three methods is the aqueous colloid suspension, which has the disadvantage of experiencing precipitation and being physicochemically unstable. This can be overcome by sublimation (freeze-drying) which dehydrates the substance and prevents particle aggregation [74]. Physicochemical characterizations such as morphological assessment, particle size, molecular weight allocation, zeta potential, pH establishment, drug dose in nanostructures, drug delivery kinetics, and long-term stability should be carried out after nanoparticles have been formulated.

**Table 4. Polymer Nanoparticles in several plants [4].**

Plant/Constituents	Parts	Carrier System	Effects
<i>Phytolacca decandra</i>	Root	PLGA-encapsulated forms (NPD)	Bioavailability is increased, and optimum chemopreventive treatment of lung cancer initiated
<i>Ocimum sanctum</i>	Leaves	Sodium alginate chitosan nanoparticles (OSN)	More effective and durable antimicrobial activity
<i>Curcuma longa</i> (curcumin)	Rhizome	poly(ethylene glycol) monoacrylate, N-vinyl-2-pyrrolidone, and N-isopropylacrylamide	A significant measured distribution of 50 nm is easily dispersed in aqueous media.
		Encapsulated in PLGA nanospheres	The encapsulation effectiveness is 90.88%, the average particle size is 45 nm and is dissolved in an aqueous without surfactant.
<i>Magnolia officinalis</i> (honokiol)	Bark, leaves	HN-loaded polymeric nanoparticles	Low hydrophobicity and free HN
<i>Gelsemium sempervirens</i> J. St.-Hil (coumarin)	Leaves	Polymeric nanocapsules	Enhanced bioavailability to that of the free active constituent

(Table 6) cont....

Plant/Constituents	Parts	Carrier System	Effects
<i>Harungana madagascariensis</i> Lam. Ex Poir	Leaves	Poly (D,L-lactide-co-glycolide) (PLG) nanoparticles	Bacterial growth is reduced
<i>Cuscuta chinensis</i> Lam.	Seed	Nanosuspension	Antioxidant activity is increased
<i>Ginkgo biloba</i> (quercetin)	Leaves	<ul style="list-style-type: none"> <li>• Polyvinyl alcohol (PVA)</li> <li>• Eudragit® E (EE) of Nanoprecipitation</li> </ul>	Improved yield and the efficiency of encapsulation exceeds 99%.
<i>Camptotheca acuminata</i> Decne (camptothecin)	Bark	Hydrophobically modified glycol chitosan (HGC)	Loading efficiency exceeds 80%
<i>Polygala senega</i>	Rhizome	Encapsulated by PLGA.	Bioavailability is increased

## Dendrimers

Dendrimers are branched macromolecules with a highly symmetrical/regular nano-size and a structure both homogeneous and monodispersed. Dendrimers are also described as nano-sized globular molecules possessing unique 3D shapes Fig.(2), characterized by low dispersity and multivalence with compositions that can be modified according to the desired purpose. Their structure is divided into core, branched repetitive unit layers, and corona. This drug delivery system is preferred due to its flexibility, shape, functional group, size, and a number of generations. Moreover, it is highly attractive [77].




Fig. (2). 3D dendrimer shapes [78].

The mechanism of dendrimer release in drug administration involves the following sequence: (1) drug molecules are trapped in the dendrimer cavity precipitating an increase in hydrophobic molecule solubility, (2) drug molecules are conjugated with functional groups on the outer shell and their delivery rate is controlled. This system has advantages such as the ability to increase the diameter linearly and to

achieve a rounder shape [76]. In addition, dendrimers can prevent A $\beta$  peptide fibrillation by blocking aggregation. This is evidenced by Wasiak *et al.* by modifying the aggregation of A $\beta$  peptide and MAP-Tau protein in cationic phosphorus dendrimers [78]. Both peptides are the main conducive agents for DA. The presence of a desiccant in the dendrimers system may also reduce the toxicity of aggregated A $\beta$  peptides. The formulation of nanoparticles of phytoconstituents can be seen in Table 5.

**Table 5. Nanoparticle formulation on phytoconstituents [79].**

Phytoconstituents	Nano/Submicrocarriers	Effects
Curcumin	SLNs	Oral bioavailability is more effective
Curcuminoids	SLNs	The release of curcuminoids as anticancer and antioxidants is prolonged.
Quercetin	Solid lipid nanoparticles SLNs	Five times greater QU-SLN bioavailability
	NLCs	NLCs have a prolonged-release, and high potency for the dermal release system.
	Liposomes	Antioxidant activity is increased, and the drug release is 74 times higher.
Glycyrrhizin acid	Nanoparticles	The bioavailability of anti-inflammatory and antihypertensive activity is improved.
Taxel	Nanoparticles	Continuous blood circulation and huge accumulation in tumors.
Camptothecin	Nanoparticles	Anticancer activity is improved.
Berberine	Nanoparticles	Sustained drug release and anticancer activity (Fukuda).
Silymarin	Liposome	More effective than silymarin suspension
Artemisinin	Nanocapsule	Anticancer activity

## THERAPEUTICAL APPLICATION

Nanoparticle drug formulation development has proved beneficial in the treatment of several diseases such as cancer, AIDS and HIV, in addition, to advances in nutraceutical delivery and diagnostic testing. Nanoparticle size varies from 100 to 500 nm. Nanoparticles can be improved to become intelligent systems, excellent therapeutic and imaging packaging agents, and assuming stealth properties by manipulating the size, surface characteristics, and materials used. This system can conduct drugs to the target tissues and provide controlled-release therapy according to a continuous target in order to reduce the degree of drug toxicity and improve patient compliance [80].

## **Cancer**

Cancer is a complex disease that is difficult to cure due to the ability of malignant cells to divide and multiply rapidly and uncontrollably. The types of cancertherapy commonly administered to patients, both through drugs and chemotherapy, produce side effects that destroy normal cells such as those in the intestinal epithelium and hair follicles [81]. Nanoparticle development offers the prospect of a breakthrough in chemotherapy through medication delivery to the site of a tumor or a specific cell group to prevent toxic impact on another healthy organ and other tissues [82]. Micelles represent the optimum means of dissolving an insoluble drug because the nucleus is hydrophobic while the shell is hydrophilic. The PEGylated micelle surface enhances the ability of thenanocarrier to pass through tumor blood vessels and inflamed tissue by passive transport, thereby delivering a higher dose of tumor therapy. Examples of polymermicelles, including anti-cancer medications are NC-6004, NK105, NK012, NK911, SP1049C [83], and Genexol-PM [84].

Dendrimer system-based nanoparticle therapy can increase the cytotoxic drug therapeutic index through the use of biocomponents and the reduction in PEGylation, glycosylation, acetylation, and various amino acids [85, 86]. Nanoparticles, namely carbon nanotubes (CNTs), contain allotropic forms of carbon with a cylindrical frame and a number of sheets in concentric, which can be categorized as carbon nanotubes with associated walls (SWCNTs) and multiwalled carbon nanotubes (MWCNTs) [87, 88]. Carbon nanotubes have a highly hydrophobic hollow interior through which water-insoluble medications can easily pass.

## **Rheumatoid**

Rheumatoid arthritis (RA) is an autoimmune inflammatory disease of the joints due to persistent polycarticular inflammation in synovial tissues, which causes progressive deterioration of the articular cartilage and bone [89]. RA occurs due to both genetic and environmental factors [90] and an abnormal immune response leading to synovial inflammation and joint damage.

Currently available pharmaceutical drugs are administered *via* conventional dosage forms and provide therapeutic advantages to only a suboptimal level, thus posing challenges and barriers to the treatment of RA. This requires a new drug delivery strategy design for the development of a useful, targeted and safe drug delivery system with enhanced therapeutic performance [89, 91]. Nanomedicines can act as the carriers of drug delivery for effective RA management because they have unique drug delivery characteristics and are considered a very promising alternative to conventional drug therapy [92]. Among the several available RA

drug delivery routes, topical nanomedicines are more advantageous because of their greater skin retention ability, targeted specific actions, reduced drug doses, lower side effects, increased acceptance, and higher patient adherence [91].

Oral administration of pomegranate extract is an effective treatment for cartilage damage because the extract contains ellagitannins, quercetin, ellagic acid, gallic acid, and polyphenols [93], which support downregulatory activities against JNK-MAPK and NF- $\kappa$ B. Thymoquinone (TQ) from *Nigella sativa* seeds has been shown to produce beneficial effects on inflammatory disorders including IBD, RA, and osteoarthritis [94] through the inhibition of serum IL-1 $\beta$  and TNF- $\alpha$  levels in RA [95]. Resveratrol is a natural polyphenol compound obtained from grape skin (*Vitis vinifera*) and *Polygonum cuspidatum* root. Intra-articular resveratrol injection has been demonstrated to have potent effects against arthritis by slowing IL-1-induced apoptosis, ROS, tumor protein (p53), LTB-4, PGE2, and MMPs in animal models [96]. Hesperidin is a citrus flavonoid reported to have therapeutic benefits *vis-a-vis* arthritis through the inhibition of secondary leg swelling and downregulation of TNF- $\alpha$  production, IL-1, and IL-6 [97]. Curcumin is a tetraterpenoid obtained from *Curcuma longa*, which has anti-inflammatory, antioxidant, and anticancer properties [98]. Green Tea Extract (GTE) produces antiarthritic effects due to the presence of nontoxic epigallocatechin-3 gallate (EGCG) through the inhibition of IL-1-induced delivery of glycosaminoglycans and nitric oxide synthase stimulated by IL-1 (iNOS), nitric oxide, and JNK action [99]. Celastrol is a pentacyclic triterpene of *Trypterygium wilfordii* and has antitumor and anti-inflammatory effects through the downregulation of caspase-1 and inhibition of NF- $\kappa$ B activation [100]. Gambogic acid (GA) is a polyprenylated xanthone containing resin derived from *Garcinia hanburyi* and *Garcinia Morella* as an antiarthritic molecule by inhibiting the secretion of IL-1 $\beta$  and TNF. Synomenine is an alkaloid obtained from *Sinomenium acutum*. It is effective for RA therapy by suppressing IL-6, MMP-2, and MMP-9 in an animal model of rheumatism [101]. *Centella asiatica* contains asiaticoside, madecassoside, centelloside, and asiatic acid (triterpenoids), which are active as anti-inflammatory [102].

The consolidation of phytoconstituents like resveratrol, gambogic acid, thymoquinone, selastrol, hesperidin, curcumin, and polyphenols in a dose-dependent manner has great potential in RA pharmacotherapy through inflammatory mediators such as cytokines, NF- $\kappa$ B, nitric oxide (NO), chemokines, arachidonic acid (AA), adhesion molecules, and lipoxygenase (LOXs). Phytoconstituents have several limitations, such as non-uniform dosage, poor bioavailability, higher metabolism, and greater distribution characteristics. Limited data is available on the concentration of polyphenols in human tissue [103], *i.e.*, 2-20%. The majority of polyphenols are metabolized directly by methylation,

glucuronidation, sulfation, and elimination by the liver, resulting in low bioavailability [103]. Oral administration of cumin causes low plasma levels as opposed to intravenous administration [22]. Resveratrol is metabolized by the small intestines, with its rapid metabolism [104] being detected in serum and plasma at a concentration of 491 90 ng/ml. Quercetin is detectable in plasma in glucuronides and sulfates unconjugated forms [105]. Herbs for RA have limited solubility and permeability, which have a higher metabolism, and have both unsuitable doses and poor bioavailability [104, 105]. This bioactive incorporation has low water solubility and high metabolism. These drawbacks can be overcome by using nano/submicrocarrier-based drug delivery technology, which maximizes increased bioavailability, greater stability, and greater efficacy without systemic side effects [91].

To overcome the limitations of curcumin, solid lipid nanoparticles are used to effectively lower leg volume through the regulation of the oxide-inflammatory cascade and immunomodulators [106]. The development of proniosomes containing curcumin (curcumin incorporated into a nanoemulsion gel) by the transdermal route can increase skin permeation fourfold [107]. Poly (lactide-c-glycolide) (PLGA) polymer-assisted nanoparticles on thymoquinone increase the entrapment efficiency to 97.5 [108]. Microemulsion-based hydrogel on synomenine is able to suppress leg swelling through the inhibition of TNF- $\alpha$ , IL- 1, and PGE<sub>2</sub> [109]. Total paeony glucoside (TGP) incorporated into the microemulsion can increase poor oral bioavailability (3-4%) [110], leading to stability in GIT [111]. The development of nanosphere-based hydrogels and solid lipid nanoparticles in Tetrandrine has been proven to increase effectiveness [112]. In addition, the ethosome of this compound has a skin permeation of 2.1 times higher than its liposome form [113]. *Tripterygium wilfordii* Hook F (TWHF) containing triptolide (TP) is incorporated into a microemulsion based hydrogel to increase its narrow therapeutic index [114]. The medical nano/submicrons loaded in the phytoconstituent to reduce limitations in RA therapy are mentioned in Table 6.

**Table 6. Nano/submicron loading to reduced limitations on RA therapy [91].**

Phytoconstituents	Nano/submicrocarriers	Remarkable Effects
Curcumin	Solid lipid nanoparticles	Extremely effective for the treatment of arthritis in rats by significantly reducing paw volume through the down-regulation of oxide-inflammatory and immune-modulatory cascade
	Nanoemulsion gel	Fourfold higher skin permeation and skin retention compared to curcumin solution in oil
	Proniosomes	Higher permeation through rat skin detected.

(Table 8) cont.....

Phytoconstituents	Nano/submicrocarriers	Remarkable Effects
Thymoquinone	Polymeric nanoparticles	97.5% entrapment efficiency (EE) is achieved. Furthermore, higher potency as compared to thymoquinone alone is obtained.
Sinomenine	Microemulsion-based hydrogel	Greater beneficial effects are produced by suppressing paw swelling through the inhibition of TNF- $\alpha$ , IL-1, and PGE <sub>2</sub>
Total glucosides of paeony (TGP)	Microemulsion	Bioavailability and stability-related problems are overcome by micro-emulsion, which also enhances drug stability in GIT and absorption
Tetrandrine	Nanospheres-based hydrogel	Absorption enhanced
	Solid lipid nanoparticles	Absorption enhanced
	Ethosomes	2-to-1 higher skin permeation in comparison to liposomes
Triptolide (TP)	Microemulsion-based hydrogel	High efficacy against RA is achieved. Furthermore, no significant toxicity was discovered during the study.
	SLNs	Rat paw volume is significantly reduced, and a protective effect against hepatotoxicity is achieved

### Nutraceutical Delivery

Nutraceuticals are standardized components derived from food and consumed as a complement to allopathic therapies, which provide additional health benefits and reduce the risk of chronic disease [115]. The bioavailability and efficacy of nutraceuticals administered orally are influenced by the interaction of the matrix with food, their solubility in water, epithelial permeability, and degradation/metabolism [116]. They are lipophilic molecules that are soluble in fat (A, D, E, and K), and polyunsaturated lipids. Nanoparticle formulations in nutraceuticals [116, 117] can reduce their limitations, enabling their use as anti-inflammatories, antioxidants, antiapoptotic, and antiangiogenics.

The nanotechnology applications of nutraceutical preparations relate to nutrient delivery, food contact materials, nutrient bioavailability, security devices, sensor diagnostics, vitamin and mineral fortification, and nanoencapsulation of flavor and aromas [118], while a summary of the potential formulations of nutraceuticals as nanomaterials can be seen in Table 7.



**Table 7. Nutraceutical formulations [118].**

<b>Phytoconstituents</b>	<b>Nano/submicrocarriers</b>	<b>Remarkable Effects</b>
Hydrophobins (Hyd)- Vitamin D <sub>3</sub>	Nanoencapsulation	<ul style="list-style-type: none"> <li>• A potential nano-transport of hydrophobic nutraceuticals to food beverage enrichment has been discovered using Hyd.</li> <li>• Hyd provides significant vitamin D<sub>3</sub> care.</li> </ul>
Folic acid with whey protein and commercial resistant starch	Nanoencapsulation	Greater encapsulation efficiency increases folic acid stability. Bioactive stabilization is enhanced.
DL- $\alpha$ -tocopheryl acetate and $\beta$ -carotene	Pluronic-127 and poly--caprolactone envelop nanocapsule through emulsification- diffusion method (EDM)	EDM is a promising method for the preparation of nanoparticles for use in food materials
Vitamin D <sub>3</sub> entrapped with whey protein NPs of different calcium concentrations	Nanoencapsulation	Vitamin D <sub>3</sub> with significant stability can be used in the clear beverage instead of as an enrichment agent.
Calcium and folic acid	Dual nutraceutical nanomaterial	To provide a good supply of nutrients important to human health
$\beta$ -carotene, folic acid, curcumin and ergocalciferol	Protein-polysaccharide soluble nanocomplex	To intensify antioxidant activity
Carotenoids	Lipid nanocarriers	The high potency of clinical applications of novel delivery systems for lipophilic plant extracts
CoQ10	Lipid-free nanoformulation	Effective transportation to increase the oral bioavailability of CoQ10
Long-chain fatty acids and CoQ10	Nanoemulsion	Nanoemulsion delivery systems increase the oral bioavailability of lipophilic nutraceuticals
Omega-3-fatty acids and oil-soluble vitamins	Biopolymeric nanogels	<ul style="list-style-type: none"> <li>• Encapsulation and shield bioactive applied only to food-grade substance</li> <li>• The fabricated system remedies issues surrounding food and beverage quality</li> </ul>
Curcumin	Organogel-based nanoemulsion	<p>Digestion of nanoemulsion is rapid and complete</p> <p>The oral bioavailability of curcumin improves</p> <p>Applied to dietary supplements, functional foods, and pharmaceutical industries</p>
$\alpha$ -tocopherol	Supercritical assisted nanosuspension	Improves dissolution rate, bioavailability and stability

(Table 9) cont.....

Phytoconstituents	Nano/submicrocarriers	Remarkable effects
(-)-epigallocatechin-3-gallate	Protein-polyphenol coassemblies: Lactoferrin based NPs	<ul style="list-style-type: none"> <li>• LF-EGCG-nanoparticles and submicrometer have a purpose as EGCG protective transport to supervise other bioactive materials release.</li> <li>• LF-EGCG has the potency to develop food formulation based on LF as a carrier of bioactive constituents</li> </ul>
Eugenol and clove oil	COM and EM oil titration-precipitation	The formulation in microemulsion provides an oral delivery system for clove oil in homogenous, water-based, and thermodynamically stable doses
Dextran and isoflavone genistein	Enzymatic-assisted inclusion complexation method	<ul style="list-style-type: none"> <li>• DMSO-water inclusion protocol is more suitable for delivering genistein into enzymatically hydrolysed dextran</li> <li>• Increase the delivery of nutraceuticals by 11- to 141-fold due to the creation of novel H-bonds and the interaction of Van der Waals forces</li> </ul>

The impact of nanotechnology on modern life is both profound and powerful. The technological speed of nanomedicine use is achieved by utilizing several kinds of nanoparticles in the prevention, diagnosis, and treatment of a wide range of complex illnesses. Herbal medicines that had been previously struggled with formulation and delivery of their active ingredients are now starting to use the benefits of nanotechnology. Cosmetochem's Herbasec<sup>®</sup> has been launched as a liposomal standardized extract for use in cosmetics due to its antioxidant effect in preventing aging. Several other plants are also employed in the production of nanomedicines, such as white hibiscus, green tea, aloe vera, white tea, guarana, and liquorice root. There are also several naturally-produced phytochemicals used as ingredients of nanomedicines such as triterpenes in *Centella asiatica*, visnadin in *Ammi visnaga*, silymarin and Silybin in milk thistle, vhamitenosides in Hawthorn blossoms, escin  $\beta$ -sitosterol in horse chestnut, sericoside in *Terminalia sericea*, ginsenosides in *Panax ginseng*, polyphenols in grape seeds and green tea, ginkgo flavon glucosides, ginkgolides, and bilobalide in *Ginkgo biloba* [74]. This proves that phytoconstituents represent the future of nanotechnology related to drug delivery, and a new era of re-exploring and investigating the full potency of traditional herbs has begun. The advantages of nanoscience in analyzing herbal medicines include:

- increased solubility and bioavailability of active ingredients
- reducing the side effects and toxicity of active ingredients
- enhancing the stability of active ingredients with regard to targets

- improving the biocompatibility and reducing the toxicity of the formulations
- increasing nanoparticle safety, and the therapeutic index of the drug

## CONCLUSION

Poor absorption of certain phytoconstituents because they are hydrophilic and unable to pass through cell lipid membranes can be overcome by applying nanoengineering such as phytosomes, liposomes, nanoemulsions, nanoparticles, solid lipid nanoparticles, and ethosomes in increasing solubility, bioavailability, pharmacological effect, stability, effectiveness, selectivity, and drug specificity of the bioactive constituents.

## CONSENT FOR PUBLICATION

Not applicable.

## CONFLICT OF INTEREST

The author declares no conflict of interest, financial or otherwise.

## ACKNOWLEDGEMENTS

Declared none.

## REFERENCES

- [1] Matijevic E. Fine particles in medicine and pharmacy. New York: Springer 2012. [http://dx.doi.org/10.1007/978-1-4614-0379-1]
- [2] Vo TN, Kasper FK, Mikos AG. Strategies for controlled delivery of growth factors and cells for bone regeneration. *Adv Drug Deliv Rev* 2012; 64(12): 1292-309. [http://dx.doi.org/10.1016/j.addr.2012.01.016] [PMID: 22342771]
- [3] Kohane DS. Microparticles and nanoparticles for drug delivery. *Biotechnol Bioeng* 2007; 96(2): 203-9. [http://dx.doi.org/10.1002/bit.21301] [PMID: 17191251]
- [4] Bonifácio BV, Silva PB, Ramos MA, Negri KM, Bauab TM, Chorilli M. Nanotechnology-based drug delivery systems and herbal medicines: a review. *Int J Nanomedicine* 2014; 9: 1-15. [PMID: 24363556]
- [5] Bharali DJ, Siddiqui IA, Adhami VM, *et al.* Nanoparticle delivery of natural products in the prevention and treatment of cancers: current status and future prospects. *Cancers (Basel)* 2011; 3(4): 4024-45. [http://dx.doi.org/10.3390/cancers3044024] [PMID: 24213123]
- [6] Martens S, Mithöfer A. Flavones and flavone synthases. *Phytochemistry* 2005; 66(20): 2399-407. [http://dx.doi.org/10.1016/j.phytochem.2005.07.013] [PMID: 16137727]
- [7] Mignet N, Seguin J, Chabot GG. Bioavailability of polyphenol liposomes: a challenge ahead. *Pharmaceutics* 2013; 5(3): 457-71. [http://dx.doi.org/10.3390/pharmaceutics5030457] [PMID: 24300518]

- [8] Mann J, Davidson RS, Hobbs JB, Banthorpe DV, Harborne JB. Natural products: Their chemistry and biological significance. 1<sup>st</sup> ed., Longman Group UK Limited 1994.
- [9] Bruschi M, Orlandi O, Rindone M, Rindone B, Saliu F, Suarez-Bertoa R, *et al.* Podophyllotoxin and antitumor synthetic aryltetralines. Toward a biomimetic preparation. *Biomimetics learning from nature.* InTech 2010.  
[<http://dx.doi.org/10.5772/8772>]
- [10] Celotti E, Ferrarini R, Zironi R, Conte LS. Resveratrol content of some wines obtained from dried *Valpolicella grapes*: Recioto and Amarone. *J Chromatogr A* 1996; 730(1-2): 47-52.  
[[http://dx.doi.org/10.1016/0021-9673\(95\)00962-0](http://dx.doi.org/10.1016/0021-9673(95)00962-0)] [PMID: 8680595]
- [11] Summerlin N, Soo E, Thakur S, Qu Z, Jambhrunkar S, Popat A. Resveratrol nanoformulations: challenges and opportunities. *Int J Pharm* 2015; 479(2): 282-90.  
[<http://dx.doi.org/10.1016/j.ijpharm.2015.01.003>] [PMID: 25572692]
- [12] Trela BC, Waterhouse AL. Resveratrol: Isomeric molar absorptivities and stability. *J Agric Food Chem* 1996; 44: 1253-7.  
[<http://dx.doi.org/10.1021/jf9504576>]
- [13] Walle T. Bioavailability of resveratrol. *Ann N Y Acad Sci* 2011; 1215: 9-15.  
[<http://dx.doi.org/10.1111/j.1749-6632.2010.05842.x>] [PMID: 21261636]
- [14] da Rocha Lindner G, Bonfanti Santos D, Colle D, *et al.* Improved neuroprotective effects of resveratrol-loaded polysorbate 80-coated poly(lactide) nanoparticles in MPTP-induced Parkinsonism. *Nanomedicine (Lond)* 2015; 10(7): 1127-38.  
[<http://dx.doi.org/10.2217/nnm.14.165>] [PMID: 25929569]
- [15] Penalva R, Esparza I, Larraneta E, González-Navarro CJ, Gamazo C, Irache JM. Zein-based nanoparticles improve the oral bioavailability of resveratrol and its anti-inflammatory effects in a mouse model of endotoxic shock. *J Agric Food Chem* 2015; 63(23): 5603-11.  
[<http://dx.doi.org/10.1021/jf505694e>] [PMID: 26027429]
- [16] Sessa M, Balestrieri ML, Ferrari G, *et al.* Bioavailability of encapsulated resveratrol into nanoemulsion-based delivery systems. *Food Chem* 2014; 147: 42-50.  
[<http://dx.doi.org/10.1016/j.foodchem.2013.09.088>] [PMID: 24206683]
- [17] Soo E, Thakur S, Qu Z, Jambhrunkar S, Parekh HS, Popat A. Enhancing delivery and cytotoxicity of resveratrol through a dual nanoencapsulation approach. *J Colloid Interface Sci* 2016; 462: 368-74.  
[<http://dx.doi.org/10.1016/j.jcis.2015.10.022>] [PMID: 26479200]
- [18] Venuti V, Cannavà C, Cristiano MC, *et al.* A characterization study of resveratrol/sulfobutyl ether--cyclodextrin inclusion complex and *in vitro* anticancer activity. *Colloids Surf B Biointerfaces* 2014; 115: 22-8.  
[<http://dx.doi.org/10.1016/j.colsurfb.2013.11.025>] [PMID: 24321846]
- [19] Catania A, Barrajón-Catalán E, Nicolosi S, Cicirata F, Micol V. Immunoliposome encapsulation increases cytotoxic activity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells. *Breast Cancer Res Treat* 2013; 141(1): 55-65.  
[<http://dx.doi.org/10.1007/s10549-013-2667-y>] [PMID: 23959397]
- [20] Mohanty C, Sahoo SK. The *in vitro* stability and *in vivo* pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. *Biomaterials* 2010; 31(25): 6597-611.  
[<http://dx.doi.org/10.1016/j.biomaterials.2010.04.062>] [PMID: 20553984]
- [21] Carvalho DM, Takeuchi KP, Geraldine RM, Moura CJ, Torres MCL. Production, solubility and antioxidant activity of curcumin nanosuspension. *Food Sci Technol* 2015; 35(1): 115-9.  
[<http://dx.doi.org/10.1590/1678-457X.6515>]
- [22] Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MNVR. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. *Eur J Pharm Sci* 2009; 37(3-4): 223-30.

- [http://dx.doi.org/10.1016/j.ejps.2009.02.019] [PMID: 19491009]
- [23] Sasaki H, Sunagawa Y, Takahashi K, *et al.* Innovative preparation of curcumin for improved oral bioavailability. *Biol Pharm Bull* 2011; 34(5): 660-5.  
[http://dx.doi.org/10.1248/bpb.34.660] [PMID: 21532153]
- [24] Yen FL, Wu TH, Lin LT, Cham TM, Lin CC. Nanoparticles formulation of *Cuscuta chinensis* prevents acetaminophen-induced hepatotoxicity in rats. *Food Chem Toxicol* 2008; 46(5): 1771-7.  
[http://dx.doi.org/10.1016/j.fct.2008.01.021] [PMID: 18308443]
- [25] Solanki SS, Sarkar P, Dhanwani RK. Microemulsion drug delivery system: for bioavailability enhancement of ampelopsin 2012.  
[http://dx.doi.org/10.5402/2012/108164]
- [26] Gortzi O, Lala S, Chinou I, Tsaknis J. Evaluation of the antimicrobial and antioxidant activities of *Origanum dictamnus* extracts before and after encapsulation in liposomes. *Molecules* 2007; 12(5): 932-45.  
[http://dx.doi.org/10.3390/12050932] [PMID: 17873829]
- [27] Yuan ZP, Chen LJ, Fan LY, *et al.* Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. *Clin Cancer Res* 2006; 12(10): 3193-9.  
[http://dx.doi.org/10.1158/1078-0432.CCR-05-2365] [PMID: 16707620]
- [28] Pool H, Quintanar D, Figueroa J. Polymeric nanoparticles as oral delivery systems for encapsulation and release of polyphenolic compounds: Impact on quercetin antioxidant activity and bioaccessibility. *Food Biophys* 2012; 7: 276-88.  
[http://dx.doi.org/10.1007/s11483-012-9266-z]
- [29] Gali-Muhtasib H, Diab-Assaf M, Boltze C, *et al.* Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells *via* a p53-dependent mechanism. *Int J Oncol* 2004; 25(4): 857-66.  
[PMID: 15375533]
- [30] Thoppil RJ, Bishayee A. Terpenoids as potential chemopreventive and therapeutic agents in liver cancer. *World J Hepatol* 2011; 3(9): 228-49.  
[http://dx.doi.org/10.4254/wjh.v3.i9.228] [PMID: 21969877]
- [31] Rabi T, Bishayee A. Terpenoids and breast cancer chemoprevention. *Breast Cancer Res Treat* 2009; 115(2): 223-39.  
[http://dx.doi.org/10.1007/s10549-008-0118-y] [PMID: 18636327]
- [32] Kaseb AO, Chinnakannu K, Chen D, *et al.* Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. *Cancer Res* 2007; 67(16): 7782-8.  
[http://dx.doi.org/10.1158/0008-5472.CAN-07-1483] [PMID: 17699783]
- [33] Chehl N, Chipitsyna G, Gong Q, Yeo CJ, Arafat HA. Anti-inflammatory effects of the *Nigella sativa* seed extract, thymoquinone, in pancreatic cancer cells. *HPB (Oxford)* 2009; 11(5): 373-81.  
[http://dx.doi.org/10.1111/j.1477-2574.2009.00059.x] [PMID: 19768141]
- [34] Kushiro T, Shibuya M, Masuda K, Ebizuka Y. Mutational studies on triterpene synthases: Engineering lupeol synthase into  $\beta$ -Amyrin synthase. *J Am Chem Soc* 2000; 122: 6816-24.  
[http://dx.doi.org/10.1021/ja0010709]
- [35] Yang L, Sun Z, Zu Y, *et al.* Physicochemical properties and oral bioavailability of ursolic acid nanoparticles using supercritical anti-solvent (SAS) process. *Food Chem* 2012; 132(1): 319-25.  
[http://dx.doi.org/10.1016/j.foodchem.2011.10.083] [PMID: 26434296]
- [36] Alghasham AA. Cucurbitacins—A promising target for cancer therapy. *Int J Health Sci* 2013; 7(1)
- [37] Lee DH, Iwanski GB, Thoennissen NH. Cucurbitacin: ancient compound shedding new light on cancer treatment. *ScientificWorldJournal* 2010; 10: 413-8.  
[http://dx.doi.org/10.1100/tsw.2010.44] [PMID: 20209387]

- [38] Zhang C, Gu C, Peng F, *et al.* Preparation and optimization of triptolide-loaded solid lipid nanoparticles for oral delivery with reduced gastric irritation. *Molecules* 2013; 18(11): 13340-56. [http://dx.doi.org/10.3390/molecules181113340] [PMID: 24172242]
- [39] Zhang N, Wardwell PR, Bader RA. Polysaccharide-based micelles for drug delivery. *Pharmaceutics* 2013; 5(2): 329-52. [http://dx.doi.org/10.3390/pharmaceutics5020329] [PMID: 24300453]
- [40] Hu L, Xing Q, Meng J, Shang C. Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles. *AAPS PharmSciTech* 2010; 11(2): 582-7. [http://dx.doi.org/10.1208/s12249-010-9410-3] [PMID: 20352534]
- [41] Zihlif MA, Mahmoud IS, Ghanim MT, *et al.* Thymoquinone efficiently inhibits the survival of EBV-infected B cells and alters EBV gene expression. *Integr Cancer Ther* 2013; 12(3): 257-63. [http://dx.doi.org/10.1177/1534735412458827] [PMID: 23089554]
- [42] Ravindran J, Nair HB, Sung B, Prasad S, Tekmal RR, Aggarwal BB. Thymoquinone poly (lactide- $\epsilon$ -glycolide) nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potential. *Biochem Pharmacol* 2010; 79(11): 1640-7. [http://dx.doi.org/10.1016/j.bcp.2010.01.023] [PMID: 20105430]
- [43] Odeh F, Ismail SI, Abu-Dahab R, Mahmoud IS, Al Bawab A. Thymoquinone in liposomes: a study of loading efficiency and biological activity towards breast cancer. *Drug Deliv* 2012; 19(8): 371-7. [http://dx.doi.org/10.3109/10717544.2012.727500] [PMID: 23043626]
- [44] Abu-Dahab R, Odeh F, Ismail SI, Azzam H, Al Bawab A. Preparation, characterization and antiproliferative activity of thymoquinone- $\beta$ -cyclodextrin self assembling nanoparticles. *Pharmazie* 2013; 68(12): 939-44. [PMID: 24400439]
- [45] Noble CO, Guo Z, Hayes ME, *et al.* Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. *Cancer Chemother Pharmacol* 2009; 64(4): 741-51. [http://dx.doi.org/10.1007/s00280-008-0923-3] [PMID: 19184019]
- [46] Zhigaltsev IV, Maurer TN, Akhong Q, *et al.* Liposome-encapsulated vincristine, vinblastine and vinorelbine: A comparative study of drug loading and retention. *Int J Mol Sci* 2012; 13: 12598-607.
- [47] Li Y, Dong L, Jia A, Chang X, Xue H. Preparation and characterization of solid lipid nanoparticles loaded traditional Chinese medicine. *Int J Biol Macromol* 2006; 38(3-5): 296-9. [http://dx.doi.org/10.1016/j.ijbiomac.2006.03.006] [PMID: 16600362]
- [48] Gao Y, Yang X, Wang Z, Zhong Z, Hu Y, Wang Y. Supramolecular nano-encapsulation of anabasin reduced its developmental toxicity in Zebrafish. *Front Chem* 2020; 8: 134. [http://dx.doi.org/10.3389/fchem.2020.00134] [PMID: 32185162]
- [49] Jeong YI, Kim DH, Chung KD, Kim YH, Lee YS, Choi KC. Antitumor activity of trigonelline-incorporated chitosan nanoparticles. *J Nanosci Nanotechnol* 2014; 14(8): 5633-7. [http://dx.doi.org/10.1166/jnn.2014.8818] [PMID: 25935980]
- [50] Tutin F, Clewer HWB. The constituents of rhubarb. *J Chem Soc Trans* 1911; 36: 946-67. [http://dx.doi.org/10.1039/CT9119900946]
- [51] Seigler DS. *Plant secondary metabolism*. Springer Science & Business Media 2012.
- [52] Chien SC, Wu YC, Chen ZW, Yang WC. Naturally occurring anthraquinones: chemistry and therapeutic potential in autoimmune diabetes. *Evid Based Complement Alternat Med* 2015; 2015: 357357. [http://dx.doi.org/10.1155/2015/357357] [PMID: 25866536]
- [53] Limaa A, Pizzolb C, Monteirob F, Creczynski-Pasab T, Andradec G, Ribeiroc A, *et al.* Hypericin encapsulated in solid lipid nanoparticles: Phototoxicity and photodynamic efficiency. *J of*

- Photochemistry and Photobiology B. Biology (Basel) 2013; 125(1): 146-54.
- [54] Amantino CF, de Baptista-Neto Á, Badino AC, Siqueira-Moura MP, Tedesco AC, Primo FL. Anthraquinone encapsulation into polymeric nanocapsules as a new drug from biotechnological origin designed for photodynamic therapy. *Photodiagn Photodyn Ther* 2020; 31: 101815. [http://dx.doi.org/10.1016/j.pdpdt.2020.101815] [PMID: 32407889]
- [55] Suo XB, Liu Y, Wu YH, Li YX. [Liposomal encapsulation of free anthraquinones in rhizoma et radix rhei and its quality control]. *Zhong Yao Cai* 2010; 33(4): 614-6. [PMID: 20845793]
- [56] Aboalnaja KO, Yaghmoor S, Kumosani TA, McClements DJ. Utilization of nanoemulsions to enhance bioactivity of pharmaceuticals, supplements, and nutraceuticals: Nanoemulsion delivery systems and nanoemulsion excipient systems. *Expert Opin Drug Deliv* 2016; 13(9): 1327-36. [http://dx.doi.org/10.1517/17425247.2016.1162154] [PMID: 26984045]
- [57] Song F, Tang J, Geng R, *et al.* Comparison of the efficacy of bone marrow mononuclear cells and bone mesenchymal stem cells in the treatment of osteoarthritis in a sheep model. *Int J Clin Exp Pathol* 2014; 7(4): 1415-26. [PMID: 24817937]
- [58] Colmenares D, Sun Q, Shen P, Yue Y, McClements DJ, Park Y. Delivery of dietary triglycerides to *Caenorhabditis elegans* using lipid nanoparticles: Nanoemulsion-based delivery systems. *Food Chem* 2016; 202: 451-7. [http://dx.doi.org/10.1016/j.foodchem.2016.02.022] [PMID: 26920318]
- [59] Rahman M, Kumar V, Beg S, Sharma G, Katare OP, Anwar F. Emergence of liposome as targeted magic bullet for inflammatory disorders: current state of the art. *Artif Cells Nanomed Biotechnol* 2016; 44(7): 1597-608. [http://dx.doi.org/10.3109/21691401.2015.1129617] [PMID: 26758815]
- [60] Solans C, Izquierdo P, Nolla J, Azemar N, Celma MJG. Nano-emulsions. *Curr Opin Colloid Interface Sci* 2005; 10: 102-10. [http://dx.doi.org/10.1016/j.cocis.2005.06.004]
- [61] Kareparamban J, Nikam P, Jadhav A, Kadam V. Phytosome: A novel revolution in herbal drugs. *Int J Res Pharm Chem* 2012; 2(2): 299-310.
- [62] Sintov AC, Shapiro L. New microemulsion vehicle facilitates percutaneous penetration *in vitro* and cutaneous drug bioavailability *in vivo*. *J Control Release* 2004; 95(2): 173-83. [http://dx.doi.org/10.1016/j.jconrel.2003.11.004] [PMID: 14980766]
- [63] Mei Z, Chen H, Weng T, Yang Y, Yang X. Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. *Eur J Pharm Biopharm* 2003; 56(2): 189-96. [http://dx.doi.org/10.1016/S0939-6411(03)00067-5] [PMID: 12957632]
- [64] Martins S, Costa-Lima S, Carneiro T, Cordeiro-da-Silva A, Souto EB, Ferreira DC. Solid lipid nanoparticles as intracellular drug transporters: an investigation of the uptake mechanism and pathway. *Int J Pharm* 2012; 430(1-2): 216-27. [http://dx.doi.org/10.1016/j.ijpharm.2012.03.032] [PMID: 22465548]
- [65] Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. *Int J Pharm* 2009; 366(1-2): 170-84. [http://dx.doi.org/10.1016/j.ijpharm.2008.10.003] [PMID: 18992314]
- [66] Naahidi S, Jafari M, Edalat F, Raymond K, Khademhosseini A, Chen P. Biocompatibility of engineered nanoparticles for drug delivery. *J Control Release* 2013; 166(2): 182-94. [http://dx.doi.org/10.1016/j.jconrel.2012.12.013] [PMID: 23262199]
- [67] Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. *Adv Drug Deliv Rev* 2004; 56(9): 1257-72. [http://dx.doi.org/10.1016/j.addr.2003.12.002] [PMID: 15109768]

- [68] Puri A, Loomis K, Smith B, *et al.* Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. *Crit Rev Ther Drug Carrier Syst* 2009; 26(6): 523-80. [http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v26.i6.10] [PMID: 20402623]
- [69] Bhattacharyya S, Kudgus RA, Bhattacharya R, Mukherjee P. Inorganic nanoparticles in cancer therapy. *Pharm Res* 2011; 28(2): 237-59. [http://dx.doi.org/10.1007/s11095-010-0318-0] [PMID: 21104301]
- [70] Rossetti FC, Fantini MCA, Carollo ARH, Tedesco AC, Bentley MVLB. Analysis of liquid crystalline nanoparticles by small angle X-ray diffraction: evaluation of drug and pharmaceutical additives influence on the internal structure. *J Pharm Sci* 2011; 100(7): 2849-57. [http://dx.doi.org/10.1002/jps.22522] [PMID: 21337546]
- [71] Farkas E, Zelkó R, Török G, Rác I, Marton S. Influence of chlorhexidine species on the liquid crystalline structure of vehicle. *Int J Pharm* 2001; 213(1-2): 1-5. [http://dx.doi.org/10.1016/S0378-5173(00)00575-5] [PMID: 11165088]
- [72] Praça FSG, Medina WSG, Petrilli R, Bentley MVLB. Liquid crystal nanodispersions enable the cutaneous delivery of photosensitizer for topical PDT: fluorescence microscopy study of skin penetration. *Curr Nanosci* 2012; 8(4): 535-40. [http://dx.doi.org/10.2174/157341312801784203]
- [73] Bernardi DS, Pereira TA, Maciel NR, *et al.* Formation and stability of oil-in-water nanoemulsions containing rice bran oil: *in vitro* and *in vivo* assessments. *J Nanobiotechnology* 2011; 9(44): 44. [http://dx.doi.org/10.1186/1477-3155-9-44] [PMID: 21952107]
- [74] Khuda-Bukhsh AR, Bhattacharyya SS, Paul S, Boujedaini N. Polymeric nanoparticle encapsulation of a naturally occurring plant scopoletin and its effects on human melanoma cell A375. *J Chin Integr Med* 2010; 8(9): 853-62. [http://dx.doi.org/10.3736/jcim20100909] [PMID: 20836976]
- [75] Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. *Mol Pharm* 2008; 5(4): 505-15. [http://dx.doi.org/10.1021/mp800051m] [PMID: 18672949]
- [76] Senthil KP. Nano-drug delivery system: applications in veterinary medicine and animal health. *Int J Sci Environ Technol* 2016; 5: 4447-51.
- [77] Çetin M, Aytakin E, Yavuz B, Bozdağ Pehlivan S. Nanoscience in targeted brain drug delivery. In importance and application of nanotechnology-based brain drug delivery systems. *Drug Delivery across the Blood-Brain Barrier* 2017; 117–147.
- [78] Wasiaik T, Ionov M, Nieznanski K, *et al.* Phosphorus dendrimers affect Alzheimer's (A $\beta$ 1-28) peptide and MAP-Tau protein aggregation. *Mol Pharm* 2012; 9(3): 458-69. [http://dx.doi.org/10.1021/mp2005627] [PMID: 22206488]
- [79] Bhavsar S. Application of nanotechnology for phytoconstituents. *Arch Nano* 2018; 1(1): 6-7. [Review].
- [80] Rizvi SAA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. *Saudi Pharm J* 2018; 26(1): 64-70. [http://dx.doi.org/10.1016/j.jsps.2017.10.012] [PMID: 29379334]
- [81] Baudino TA. Targeted cancer therapy: the next generation of cancer treatment. *Curr Drug Discov Technol* 2015; 12(1): 3-20. [http://dx.doi.org/10.2174/1570163812666150602144310] [PMID: 26033233]
- [82] Shen B, Ma Y, Yu S, Ji C. Smart multifunctional magnetic nanoparticle-based drug delivery system for cancer thermo-chemotherapy and intracellular imaging. *ACS Appl Mater Interfaces* 2016; 8(37): 24502-8. [http://dx.doi.org/10.1021/acsami.6b09772] [PMID: 27573061]
- [83] Oerlemans C, Bult W, Bos M, Storm G, Nijsen JFW, Hennink WE. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. *Pharm Res* 2010; 27(12): 2569-89.



- [http://dx.doi.org/10.1007/s11095-010-0233-4] [PMID: 20725771]
- [84] Zhang X, Huang Y, Li S. Nanomicellar carriers for targeted delivery of anticancer agents. *Ther Deliv* 2014; 5(1): 53-68.  
[http://dx.doi.org/10.4155/tde.13.135] [PMID: 24341817]
- [85] Baker JR. Dendrimer-based nanoparticles for cancer therapy. *Hematol Am Soc Hematol Educ Program* 2009; pp. 708-19.
- [86] Cheng Y, Zhao L, Li Y, Xu T. Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives. *Chem Soc Rev* 2011; 40(5): 2673-703.  
[http://dx.doi.org/10.1039/c0cs00097c] [PMID: 21286593]
- [87] Rastogi V, Yadav P, Bhattacharya SS, *et al.* Carbon nanotubes: an emerging drug carrier for targeting cancer cells. *J Drug Deliv* 2014; 2014: 670815.  
[http://dx.doi.org/10.1155/2014/670815] [PMID: 24872894]
- [88] Sanginario A, Miccoli B, Demarchi D. Carbon nanotubes as an effective opportunity for cancer diagnosis and treatment. *Biosensors (Basel)* 2017; 7(1): 9.  
[http://dx.doi.org/10.3390/bios7010009] [PMID: 28212271]
- [89] Anderson KO, Bradley LA, Young LD, McDaniel LK, Wise CM. Rheumatoid arthritis: review of psychological factors related to etiology, effects, and treatment. *Psychol Bull* 1985; 98(2): 358-87.  
[http://dx.doi.org/10.1037/0033-2909.98.2.358] [PMID: 3901066]
- [90] Scrivo R, Di Franco M, Spadaro A, Valesini G. The immunology of rheumatoid arthritis. *Ann N Y Acad Sci* 2007; 1108: 312-22.  
[http://dx.doi.org/10.1196/annals.1422.033] [PMID: 17893995]
- [91] Rahman M, Beg S, Verma A, *et al.* Phytoconstituents as pharmacotherapeutics in rheumatoid arthritis: challenges and scope of nano/submicromedicine in its effective delivery. *J Pharm Pharmacol* 2017; 69(1): 1-14.  
[http://dx.doi.org/10.1111/jphp.12661] [PMID: 27774648]
- [92] Albuquerque J, Moura CC, Sarmento B, Reis S. Solid lipid nanoparticles: a potential multifunctional approach towards rheumatoid arthritis theranostics. *Molecules* 2015; 20(6): 11103-18.  
[http://dx.doi.org/10.3390/molecules200611103] [PMID: 26087258]
- [93] Rasheed Z, Akhtar N, Haqqi TM. Pomegranate extract inhibits the interleukin-1 $\beta$ -induced activation of MKK-3, p38 $\alpha$ -MAPK and transcription factor RUNX-2 in human osteoarthritis chondrocytes. *Arthritis Res Ther* 2010; 12(5): R195.  
[http://dx.doi.org/10.1186/ar3166] [PMID: 20955562]
- [94] Umar S, Hedaya O, Singh AK, Ahmed S. Thymoquinone inhibits TNF- $\alpha$ -induced inflammation and cell adhesion in rheumatoid arthritis synovial fibroblasts by ASK1 regulation. *Toxicol Appl Pharmacol* 2015; 287(3): 299-305.  
[http://dx.doi.org/10.1016/j.taap.2015.06.017] [PMID: 26134265]
- [95] Ahmad A, Husain A, Mujeeb M, *et al.* A review on therapeutic potential of *Nigella sativa*: A miracle herb. *Asian Pac J Trop Biomed* 2013; 3(5): 337-52.  
[http://dx.doi.org/10.1016/S2221-1691(13)60075-1] [PMID: 23646296]
- [96] Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the *in vivo* evidence. *Nat Rev Drug Discov* 2006; 5(6): 493-506.  
[http://dx.doi.org/10.1038/nrd2060] [PMID: 16732220]
- [97] Umar S, Kumar A, Sajad M, *et al.* Hesperidin inhibits collagen-induced arthritis possibly through suppression of free radical load and reduction in neutrophil activation and infiltration. *Rheumatol Int* 2013; 33(3): 657-63.  
[http://dx.doi.org/10.1007/s00296-012-2430-4] [PMID: 22527139]
- [98] Funk JL, Oyarzo JN, Frye JB, *et al.* Turmeric extracts containing curcuminoids prevent experimental rheumatoid arthritis. *J Nat Prod* 2006; 69(3): 351-5.

- [http://dx.doi.org/10.1021/np050327j] [PMID: 16562833]
- [99] Ahmed S. Green tea polyphenol epigallocatechin 3-gallate in arthritis: progress and promise. *Arthritis Res Ther* 2010; 12(2): 208.  
[http://dx.doi.org/10.1186/ar2982] [PMID: 20447316]
- [100] Salminen A, Lehtonen M, Paimela T, Kaarniranta K. Celastrol: molecular targets of thunder god vine. *Biochem Biophys Res Commun* 2010; 394(3): 439-42.  
[http://dx.doi.org/10.1016/j.bbrc.2010.03.050] [PMID: 20226165]
- [101] Tong B, Yu J, Wang T, *et al.* Sinomenine suppresses collagen-induced arthritis by reciprocal modulation of regulatory T cells and Th17 cells in gut-associated lymphoid tissues. *Mol Immunol* 2015; 65(1): 94-103.  
[http://dx.doi.org/10.1016/j.molimm.2015.01.014] [PMID: 25656802]
- [102] Wang T, Wei Z, Dou Y, *et al.* Intestinal interleukin-10 mobilization as a contributor to the anti-arthritis effect of orally administered madecassoside: a unique action mode of saponin compounds with poor bioavailability. *Biochem Pharmacol* 2015; 94(1): 30-8.  
[http://dx.doi.org/10.1016/j.bcp.2015.01.004] [PMID: 25600909]
- [103] Siddiqui MZ. *Boswellia serrata*, a potential antiinflammatory agent: an overview. *Indian J Pharm Sci* 2011; 73(3): 255-61.  
[PMID: 22457547]
- [104] Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. *Mol Nutr Food Res* 2005; 49(5): 472-81.  
[http://dx.doi.org/10.1002/mnfr.200500010] [PMID: 15779070]
- [105] Morand C, Crespy V, Manach C, Besson C, Demigné C, Rémésy C. Plasma metabolites of quercetin and their antioxidant properties. *Am J Physiol* 1998; 275(1): R212-9.  
[PMID: 9688981]
- [106] Arora R, Kuhad A, Kaur IP, Chopra K. Curcumin loaded solid lipid nanoparticles ameliorate adjuvant-induced arthritis in rats. *Eur J Pain* 2015; 19(7): 940-52.  
[http://dx.doi.org/10.1002/ejp.620] [PMID: 25400173]
- [107] Kumar K, Rai AK. Proniosomal formulation of curcumin having anti-inflammatory and anti-arthritic activity in different experimental animal models. *Pharmazie* 2012; 67(10): 852-7.  
[PMID: 23136720]
- [108] Singh A, Ahmad I, Akhter S, Ahmad MZ, Iqbal Z, Ahmad J. Thymoquinone: major molecular targets, prominent pharmacological actions and drug delivery Concerns. *Curr Bioact Compd* 2012; 8: 334-44.  
[http://dx.doi.org/10.2174/1573407211208040003]
- [109] Zhang XZ, Zhu HD, Meng SF, Pan XG. [Preparation of sinomenine microemulsion and its transdermal absorption]. *Zhongguo Zhongyao Zazhi* 2007; 32(19): 2007-10.  
[PMID: 18161292]
- [110] Zheng YQ, Wei W. Total glucosides of paeony suppresses adjuvant arthritis in rats and intervenes cytokines signaling between different types of synoviocytes. *Int Immunopharmacol* 2005; 5: 156-73.  
[http://dx.doi.org/10.1016/j.intimp.2005.03.010]
- [111] Wang X, Xue M, Gu J, Fang X, Sha X. Transdermal microemulsion drug delivery system for impairing male reproductive toxicity and enhancing efficacy of *Tripterygium Wilfordii* Hook f. *Fitoterapia* 2012; 83(4): 690-8.  
[http://dx.doi.org/10.1016/j.fitote.2012.02.006] [PMID: 22391023]
- [112] Li S, Ji Z, Zou M, Nie X, Shi Y, Cheng G. Preparation, characterization, pharmacokinetics and tissue distribution of solid lipid nanoparticles loaded with tetrandrine. *AAPS PharmSciTech* 2011; 12(3): 1011-8.  
[http://dx.doi.org/10.1208/s12249-011-9665-3] [PMID: 21811889]
- [113] Fan C, Li X, Zhou Y, *et al.* Enhanced topical delivery of tetrandrine by ethosomes for treatment of

- arthritis. *BioMed Res Int* 2013; 2013: 161943.  
[<http://dx.doi.org/10.1155/2013/161943>] [PMID: 24062995]
- [114] Chen H, Chang X, Weng T, *et al.* A study of microemulsion systems for transdermal delivery of triptolide. *J Control Release* 2004; 98(3): 427-36.  
[<http://dx.doi.org/10.1016/j.jconrel.2004.06.001>] [PMID: 15312998]
- [115] Aggarwal BB, Van Kuiken MEV, Iyer LH, Harikumar KB, Sung B. Molecular targets of nutraceuticals derived from dietary spices: potential role in suppression of inflammation and tumorigenesis. *Exp Biol Med* (Maywood) 2009; 234(8): 825-49.  
[<http://dx.doi.org/10.3181/0902-MR-78>] [PMID: 19491364]
- [116] McClements DJ, Li F, Xiao H. The nutraceutical bioavailability classification scheme: classifying nutraceuticals according to factors limiting their oral bioavailability. *Annu Rev Food Sci Technol* 2015; 6: 299-327.  
[<http://dx.doi.org/10.1146/annurev-food-032814-014043>] [PMID: 25705933]
- [117] Acosta E. Bioavailability of nanoparticles in nutrient and nutraceutical delivery. *Curr Opin Colloid Interface Sci* 2009; 14(1): 3-15.  
[<http://dx.doi.org/10.1016/j.cocis.2008.01.002>]
- [118] Gopi S, Amalraj A, Haponiuk JT, Thomas S. Introduction of nanotechnology in herbal drugs and nutraceutical: A Review. *J Nanomedicine Biotherapeutic Discov* 2016; 6(2): 1-8.  
[<http://dx.doi.org/10.4172/2155-983X.1000143>]